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ABSTRACT 
 
JON R. FEE: The Role of Protein Kinase A and Stress in Ethanol-Induced Locomotor 
Sensitization 
(Under the direction of Todd E. Thiele) 
 
 
 There is a growing body of literature dedicated to elucidating the mechanisms 
involved in behavioral sensitization. The following studies examined the ability of alterations 
in PKA signaling (via genetic knockout) and CRF signaling (via pharmacological blockade) 
to modulate ethanol-induced locomotor sensitization and restraint stress-induced cross-
sensitization.  
 Experiment 1 utilized the RIIβ knockout model to determine if alterations in PKA 
signaling affect locomotor activation in response to ethanol as well as the development of 
ethanol-induced locomotor sensitization. RIIβ-/- mice consistently showed significantly 
greater ethanol-induced locomotor activity relative to RIIβ+/+ mice. RIIβ-/- mice also showed 
increased sensitivity to ethanol-induced locomotor sensitization, an effect that may be 
dependent on genetic background and/or testing paradigm. Importantly, increased locomotor 
activity by RIIβ-/- mice was specific to ethanol injections, absent following saline injections, 
and not associated with altered blood ethanol levels. 
 Experiment 2 attempted to discern a few of the mechanisms underlying the restraint 
stress-induced cross-sensitized response to ethanol in mice. Chronic exposure to restraint 
stress (2hrs for 10 days) induced a cross-sensitized response to ethanol in two commercially 
 iii
available inbred strains of mice, C57BL/6J and DBA/2J. The RIIβ knockout mouse model 
was also utilized to test if enhanced sensitivity to stress might be a factor contributing to the 
previously observed heightened sensitivity to ethanol-induced locomotor sensitization in 
these mice. RIIβ-/- and RIIβ+/+ showed no differences in the effect of stress on ethanol-
induced locomotor activity. Finally, pretreatment with CRF Receptor 1 antagonist, CP-
154,526, prior to restraint stress sessions in male DBA/2J mice failed to block the acquisition 
of a cross-sensitized response to ethanol. 
 Experiment 3 used a CRF Receptor 1 antagonist, CP-154,526, in an attempt to block 
the acquisition and expression of ethanol-induced locomotor sensitization in male DBA/2J 
mice. Pretreatment with CP-154,526 was ineffective in blocking the acquisition of a 
sensitized response to ethanol. In contrast, pretreatment with CP-154,526 effectively blocked 
expression of a sensitized response in DBA/2J mice that had been previously sensitized to the 
locomotor stimulating effects of ethanol. These effects were not attributable to alterations in 
blood ethanol levels, and ethanol naïve DBA/2J mice when pretreated with CP-154,526 show 
no such reductions in locomotor activity in response to ethanol. 
 These experiments suggest a role for both PKA and CRF signaling in the mechanisms 
underlying ethanol-induced locomotor sensitization. Additionally, the ability of chronic 
restraint stress to elicit a cross-sensitized response to ethanol in mice is demonstrated. 
Ultimately, it remains unclear if alterations in PKA or CRF signaling are involved in the 
mechanisms associated with restraint stress-induced cross sensitization. 
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CHAPTER 1 
GENERAL INTRODUCTION 
 
Many neurotransmitters, neuromodulators, and hormones transduce their signal into 
cells by activating G-protein-coupled receptors. Following G-protein-coupled receptor 
binding, cAMP levels are either enhanced or inhibited via changes in adenylyl cyclase (AC) 
activation. This action leads to concomitant increases or decreases in cAMP-dependent 
protein kinase A (PKA) activity, respectively. PKA is a holoenzyme which consists of a 
regulatory (R) subunit homodimer and two catalytic (C) subunits (Brandon et al. 1997). In 
the mouse, PKA includes four regulatory subunits (RI, RI, RII and RII) and two 
catalytic subunits (C and C) which are expressed in tissue-specific patterns (McKnight 
1991). It has been shown that the RII- subunit is selectively expressed in brain and adrenal 
tissue in addition to adipose tissue (Sarkar et al. 1984). Sarkar and colleagues suggest that 
RII- is the predominant regulatory subunit of PKA in the central nervous system.   
The RII-/- mouse model exhibits reduced cAMP-stimulated protein kinase A (PKA) 
activity in various brain regions implicated in the pharmacological response to drugs of 
abuse, including the striatum, nucleus accumbens, amygdala, hippocampus and 
hypothalamus and generally in the cortex (Brandon et al. 1998; Thiele et al. 2000b). It has 
been proposed that the loss of the RII- subunit results in enhanced constituent PKA 
activation and in turn, enzymatic degradation of unbound catalytic subunit leading to a 
2functional loss of PKA activity. As a result, the relative distribution of other regulatory 
subunits up-regulates in an attempt to compensate for the loss of RII- (Amieux et al. 1997; 
Brandon et al. 1998). However, it stands to reason that this compensation is not full as 
evidenced by the reduced cAMP-stimulated PKA activity. These findings would suggest that 
the RII-/- model is characterized by reductions in PKA signaling. The manipulation of PKA 
activity has been shown to have several interesting behavioral consequences. There is 
consistent evidence that deletion of the RII- subunit results in a mouse that will more readily 
consume ethanol solutions compared to wildtype littermate controls (Fee et al. 2004; Thiele 
et al. 2000b).  In our most recent study, it was found that these genotype differences in 
consumption were not reliably predicted by basal levels of anxiety despite the observation 
that blunted PKA activity and phosphorylated CREB (pCREB) in the amygdala are 
associated with increased anxiety-like behavior (Pandey et al. 2003). RII-/- mice consistently 
show reductions in their sensitivity to the sedative properties of ethanol (Fee et al. 2004; 
Thiele et al. 2000b). Recently, our lab discovered that RII-/- mice are also more sensitive to 
the acquisition of ethanol-induced locomotor sensitization (Fee et al. 2006). These data are 
complemented by an earlier finding by McKnight and colleagues that RII-/- mice are more 
sensitive to amphetamine-induced locomotor sensitization (Brandon et al. 1998). Taken 
together, these data would suggest that manipulation of PKA signaling via the deletion of the 
RII- subunit increases sensitivity to the sensitization that accompanies repeated exposure to 
drugs of abuse. 
Manipulation of PKA signaling via deletion of the RII- subunit results in a mouse 
model that is more susceptible to the acquisition of locomotor sensitization following 
repeated amphetamine (Brandon et al. 1998) and ethanol (Fee et al. 2006) exposure. 
3Amphetamine exposure during the rat preweanling phase has been shown to produce 
persistent reductions in PKA activity in the accumbens and dorsal striatum (Crawford et al. 
2000). Interestingly, these reductions in PKA function were not linked to a sensitized 
response to amphetamine, however, these rats only received a single dose of amphetamine 
and it is possible that the reduction in PKA activity could have promoted behavioral 
sensitization had repeated injections been administered. The ventral tegmental area (VTA) 
has also been implicated as a brain region in which PKA activity mediates the expression of 
amphetamine sensitization. Co-injection of the PKA inhibitor, Rp-cAMPS, blocked the 
sensitization induced by intra-VTA amphetamine injections and intra-VTA administration of 
the PKA activator, Sp-cAMPS, augmented the sensitization caused by peripheral 
amphetamine administration (Tolliver et al. 1999). These data suggest the possibility of 
regional specificity in PKA’s involvement in the regulation of sensitivity to sensitization. A 
similar conclusion has been drawn concerning the role of PKA in modulating sensitivity to 
the sedative properties of ethanol (Rodan et al. 2002). Taken together, these observations 
suggest a role for PKA signaling in the mediation of behavioral sensitization caused by 
repeated application of drugs of abuse. 
Repeated stress has been shown to blunt PKA activity in specific brain regions. It was 
recently discovered that rats exposed to inescapable stress (IS), a model of learned 
helplessness, show decreased PKA activity in the hippocampus and cortex. The continued 
presence of learned helplessness behavior following IS was linked to persistent reductions in 
PKA activity. Reductions in PKA signaling appear to be linked to reductions in the 
expression of RII-, C=, and C- subunits (Dwivedi et al. 2004). Based on these data, it could 
be suggested that, at birth, RII-/- mice resemble animals that have been exposed to repeated 
4stressors because both models show reduced cAMP-dependent PKA signaling in the cortex 
and hippocampus. In a related study, implantation of a corticosterone pellet in 
adrenalectomized rats decreased cAMP binding to PKA. Adrenalectomy led to increases in 
cAMP binding to PKA. Additionally, corticosterone treatment led to reduced expression of 
the PKA subunits RII-, RI=, and C- in the cortex and the hippocampus of rats (Dwivedi and 
Pandey 2000). These data also suggest that repeated or prolonged exposure to stress leads to 
persistent reductions in PKA activity. In contrast, it has been shown that repeated 
unpredictable stress increased levels of cAMP-dependent protein kinase activity in the 
nucleus accumbens (Ortiz et al. 1996).  
PKA is involved in the regulation of receptors that mediate the stress response. PKA 
can phosphorylate and induce the transcription of the progesterone receptor (Denner et al. 
1990). In addition, PKA has been shown to affect to the regulation of mineralocorticoid 
receptors (Massaad et al. 1999). Additionally, glucocorticoid receptor function in specific 
cell lines is believed to be mediated by cAMP-dependent protein kinase (Gruol and Dalton 
1984). PKA can also enhance the DNA binding activity of glucocorticoid receptors 
(Rangarajan et al. 1992). Taken together these data suggest that PKA activity is important in 
the regulation of receptors involved in the stress response.  
PKA has also been shown to play an important role in the regulation of the adrenal 
cortex. It has been suggested that PKA is critical in the growth and growth maintenance of 
the adrenal cortex, in that a single gene mutation for PKA results in hyperplasia (Keegan and 
Hammer 2002). Interestingly, this was one of the regions identified for its predominance of 
RII- subunit expression (Sarkar et al. 1984). These studies suggest a critical role for PKA 
and specifically the RII- subunit in the proper regulation of the hypothalamic-pituitary-
5adrenal (HPA) axis as well as the cellular consequences of stress exposure. The HPA axis is 
the well characterized neuroendocrine system which responds to stress in a cascade of events 
resulting ultimately in corticosteroid release. A detailed assessment of the markers of HPA 
axis function in RII-/- mice before and after exposure to stress would greatly benefit the field 
by determining how complete loss of the RII- subunit affects stress related signaling.  
 There is considerable evidence in the literature suggesting a role for PKA activity in 
the regulation of HPA axis activity. It has been suggested that the effects of diazepam on 
HPA axis activity are mediated via cAMP-dependant PKA activity in the hypothalamus 
(Vargas et al. 2001). PKA activity has also been put forward as a potential mechanism 
underlying the diminished hippocampal activity thought to be associated with the HPA axis 
hyperactivity in depression (Perera et al. 2001). Specifically, ethanol has been shown to 
increase PKA and cAMP activity and, in turn, increase corticotropin releasing factor (CRF) 
peptide secretion (Li et al. 2005). Additionally, PKA activity has been shown to play an 
essential role in CRF mediated decreased expression of CRF receptor 1 mRNA in part via the 
phosphorylation of cAMP response element binding (CREB) (Kasagi et al. 2002). However, 
other investigators have suggested a role for protein kinase C (PKC) and PKA in ACTH 
release (Iwabuchi et al. 1999), and a role for G protein receptor kinase (GRK) in the activity 
of CRF type 1 receptors (Dautzenberg et al. 2001). 
A significant literature exists suggesting that direct manipulation of corticotropin 
releasing factor (CRF) will influence the acquisition and expression of drug-induced 
locomotor sensitization. Sensitization has been defined as the long-lasting and progressive 
enhancement of the locomotor and motivational responses to a drug following repeated 
administration (Kalivas and Stewart 1991). Intracerebroventricular (i.c.v.) administration of 
6the CRF antagonist, =-helical CRF, reduced stereotypic response to amphetamine following 
repeated restraint stress in rats (Cole et al. 1990b). In contrast, an augmentation of HPA axis 
signaling via pharmacological manipulation can result in the expression of sensitized 
behaviors. I.c.v. administration of CRF rather than subcutaneous administration of CRF leads 
to long-term locomotor sensitization to D-amphetamine (Cador et al. 1993). Similarly, 
microinfusion of CRF into the shell of the nucleus accumbens of rats led to a prolonged 
increase in general locomotor activity (Holahan et al. 1997). It also appears that a blockade 
of endogenous CRF signaling via administration of CRF receptor 1 antagonist, CP-154,526, 
will reduce cocaine-induced locomotor sensitization and relapse behavior (Przegalinski et al. 
2005). These approaches have yielded fruitful results, and further investigation is necessary 
to more fully understand the role of CRF signaling and its effects within and outside of HPA 
axis activity in the acquisition and expression of cross-sensitized drug responses. 
It is been shown that exposure to ethanol leads to an activation of the HPA axis 
(Ogilvie et al. 1997; Pruett et al. 1998). For this reason, it is important to consider stress-
related signaling mechanisms when investigating the acquisition of ethanol-induced 
locomotor sensitization. It has been shown that restraint stress can substitute for ethanol 
injections in an ethanol sensitization paradigm suggesting that many of the same endogenous 
mechanisms are activated by ethanol and stressors. This study also found that pretreatment 
with the glucocorticoid receptor antagonist, RU38486, could block the expression of ethanol-
induced locomotor sensitization (Roberts et al. 1995). This would suggest overlapping 
pathways between the molecular mechanisms involved in stress and ethanol exposure with 
respect to sensitization. This critical role for stress in the expression of sensitization is also 
found in the cocaine literature. Administration of a corticosterone synthesis inhibitor, 
7metyrapone, blocked the increased corticosterone levels and the sensitized locomotor 
response to cocaine in rats maintained on 90% food restriction (Marinelli et al. 1996). 
Repeated administration of various stressors (restraint, handling, and social defeat) has been 
shown to sensitize the locomotor response to morphine (Stohr et al. 1999). However, a 
sensitized corticosterone response is not necessary for the expression of long-term (3 weeks) 
amphetamine sensitization as evidenced by the lack of a correlational relationship between 
corticosterone levels and locomotor activity (Schmidt et al. 1999). Although corticosterone 
levels were not predictive, this does not necessarily mean that extended exposure to stress did 
not manifest itself in changes in receptor affinity or population. A larger picture of stress 
signaling, as provided by numerous markers, is necessary to elucidate the role of stress in the 
acquisition and expression of locomotor sensitization. 
In 2001, Lessov and colleagues demonstrated that locomotor sensitization was 
possible in C57BL/6 mice. This was a model that had otherwise not shown sensitization and 
was used as an argument against the association between ethanol locomotor sensitization and 
ethanol reward based on the fact that C57BL/6 mice are notoriously high drinkers (Phillips et 
al. 1994). Pure C57BL/6 mice were shown to increase their ethanol preference after the 
acquisition of locomotor sensitization. There was an opposite effect on the preference of 
DBA/2J mice, a strain that is relatively easy to sensitize (Lessov et al. 2001). Additionally, a 
study of high alcohol preferring (HAP) and low alcohol preferring (LAP) mice found that 
high ethanol preference was predictive of the acquisition of ethanol-induced locomotor 
sensitization (Grahame et al. 2000). The RII-/- mouse model is a third example of a high 
ethanol preferring mouse that exhibits heightened susceptibility to locomotor sensitization. In 
fact, ethanol-induced locomotor sensitization in RII-/- mice maintained on a C57BL/6 
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(2001) study (lower dose, bi-weekly verses daily injections). Deletion of the dopamine D2 
receptor (Drd2) also enhances ethanol-induced locomotor sensitization on a C57BL/6 
background which resulted in the elimination of an initially reduced ethanol preference 
compared to wildtype mice. However, the effect of the Drd2 deletion had no effect on a 129 
background suggesting an epistatic interaction (Palmer et al. 2003). With only a few 
exceptions, these studies suggest an interesting interaction between voluntary drug self-
administration and the acquisition of sensitization or vice versa.   Not only does the RII-/- 
mouse readily self-administer ethanol, this model also lacks the critical subunit that has been 
implicated in the proper regulation of endogenous stress signaling. The RII-/- mouse model 
allows for the very unique study of stress in ethanol-induced locomotor sensitization that is 
currently not available otherwise. 
The following experiments will attempt to elucidate mechanisms (PKA and CRF) 
which we propose to be involved in ethanol-induced locomotor activation and sensitization. 
Given the availability of the RII- knockout model, a role for PKA activity in ethanol-induced 
locomotor sensitization will be investigated. Additional focus will be given to the ability of a 
CRF receptor 1 antagonist, CP-154,526, to block the acquisition and expression of ethanol-
induced locomotor sensitization. Together these experiments will demonstrate a novel role 
for PKA signaling and CRF receptor activation in the sensitized locomotor responses that 
accompany repeated exposure to ethanol. A final set of experiments will look at the ability of 
stress to serve as a sensitizing agent in a series of restraint stress-induced cross-sensitized 
responses to ethanol.  
 
CHAPTER 2
EXPERIMENT 1: INVOLVEMENT OF PROTEIN KINASE A IN
ETHANOL-INDUCED LOCOMOTOR ACTIVITY AND SENSITIZATION
Introduction
Behavioral sensitization has been defined as the long-lasting and progressive
enhancement of the locomotor and motivational responses to a drug following repeated
administration (Kalivas and Stewart 1991). Over the past twenty years, many studies have
demonstrated the ability of repeated ethanol exposure to elicit locomotor sensitization in
mice (Crabbe et al. 1992; Cunningham and Noble 1992; Lister 1987; Phillips et al. 1995).
Interestingly, a genetic predisposition to alcoholism has been associated with increased
sensitivity to this phenomenon. Sons of alcoholics, when compared to sons of non-alcoholics,
have been shown to be more sensitive to increases in locomotor activity that emerge over the
course of repeated ethanol administrations (Newlin and Thomson 1991). It has been
suggested that increased sensitivity to behavioral sensitization may be an underlying
mechanism that increases the risk for developing drug dependence. According to this view,
repeated exposure to a drug promotes neural reorganization leading to a hypersensitive state
in brain reward circuitry (Robinson and Berridge 1993; 2000; 2001).
Studies of neural plasticity have shown that intracellular cAMP-dependent protein
kinase A (PKA) modulates neurophysiological alterations that are responsible for the
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sensitization associated with repeated exposure to noxious stimuli (Castellucci et al. 1980).
As such, it is possible that PKA signaling also modulates the neural plasticity that is believed
to be responsible for the expression of drug-induced behavioral sensitization. In fact, some of
the neurochemical systems that have been implicated in drug-induced locomotor stimulation
and behavioral sensitization involve G-protein-coupled receptors that recruit PKA signaling,
including dopamine (Broadbent et al. 1995; Broadbent et al. 2005; Hamamura et al. 1991;
Itzhak and Martin 1999; Lessov and Phillips 2003; Mattingly et al. 1994; Palmer et al. 2003),
adenosine (Chen et al. 2003), serotonin (Auclair et al. 2004), opioid (Camarini et al. 2000)
and GABA (Broadbent and Harless 1999). Theoretically, since PKA signaling is a basic
neuronal mechanism influenced by different neurochemical pathways, neurobiological
responses to drugs of abuse with different mechanisms of action on PKA may be a basis for
drug cross-sensitization (Itzhak and Martin 1999; Lessov and Phillips 2003; McDaid et al.
2005; Muschamp and Siviy 2002).
It is currently unknown if PKA signaling modulates the stimulant effects and/or
behavioral sensitization caused by ethanol administration. To address this question, we
examined the effects of repeated ethanol administration on locomotor activity in a PKA-
mutant mouse model. In the mouse, PKA includes four regulatory subunits (RI, RI, RII
and RII) and two catalytic subunits (C and C) which are expressed in tissue-specific
patterns (McKnight 1991). Use of mice lacking the RII subunit of PKA (RII-/-) allows for
the assessment of locomotor sensitization in a model shown previously to have reduced
cAMP-stimulated PKA activity in brain regions implicated in behavioral sensitization
including the striatum and the nucleus accumbens (Brandon et al. 1998; Thiele et al. 2000b).
We have previously shown that RII-/- mice exhibit enhanced ethanol preference and
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consumption as well as reduced sensitivity to ethanol-induced sedation when compared with
wildtype littermate control mice (Fee et al. 2004; Thiele et al. 2000b). Several recent studies
have suggested a positive correlation between ethanol preference and ethanol-induced
locomotor sensitization in mice (Grahame et al. 2000; Lessov et al. 2001; Palmer et al. 2003).
Thus, because RII-/- mice show increased ethanol preference, we hypothesized that RII-/- 
mice would show increased sensitivity to the stimulant effects of ethanol and enhanced
ethanol-induced locomotor sensitization.
Because the expression of phenotypes can depend on the genetic background of the
knockout mouse model (Fee et al. 2004; Palmer et al. 2003; Thiele et al. 2004), we evaluated
ethanol-induced locomotor activity and sensitization in RII-/- and RII+/+ mice maintained
on differing genetic backgrounds. The sensitization paradigm developed in our laboratory
involved bi-weekly ethanol injections. However, due to the fact that subtle differences in
testing paradigm can lead to dramatic differences in observed behavior (Rustay et al. 2003),
we also employed an alternate sensitization paradigm that is commonly used in other
laboratories (Lessov et al. 2001; Meyer et al. 2005).
Methods
Animals
RII-/- mice were created through the disruption of the RII gene by homologous
recombination in embryonic stem cells from 129/SvJ mice (Brandon et al. 1998). Chimeras
were bred with C57BL/6J mice to obtain heterozygotes (50% 129/SvJ x 50% C57BL/6J).
These heterozygotes were backcrossed with C57BL/6J mice over 8 generations to yield
RII+/- mice on a ~100% C57BL/6J genetic background. For some experiments described
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here, non-littermate RII+/- mice on the 100% C57BL/6J background were bred, to provide
RII-/- and RII+/+ F2 littermate mice. Additional experiments involved RII-/- and RII+/+ F2
littermate mice on a 50% 129/SvEv x 50% C57BL/6J background that were created by
crossing the RII-/- mice with wild-type 129/SvEv mice. The genetic status of all mice was
determined using polymerase chain reaction (PCR) procedures described elsewhere (Thiele
et al. 2000b). Animals weighed approximately 20 g, were 3 to 6 months of age at the
beginning of experiments, and were individually housed in polypropylene cages with
corncob bedding. Mice had ad libitum access to water and standard rodent chow (Tekland,
Madison, WI) except where noted. The colony room was maintained at approximately 22° C
with a 12h:12h light:dark cycle with lights off at 3:00 pm. All procedures used in the present
study were in compliance with the National Institute of Health guidelines, and all protocols
were approved by the University of North Carolina Institutional Animal Care and Use
Committee.
Ethanol-Induced Locomotor Activation: Test Chamber Injections
Drug-naïve RII-/- (male, n = 14; female, n = 14) and RII+/+ (male, n = 13; female, n = 13)
mice on a pure C57BL/6J background as well as RII-/- (male, n = 12; female, n = 15) and
RII+/+ (male, n = 13; female, n = 15) mice on a mixed 129/SvEv x C57BL/6J background
were tested during the light phase of their light:dark cycle. All animals were transported to
the testing room in their home cages and allowed to habituate for at least 35-min prior to
testing. A fan provided masking noise in the testing room. Mice were removed from their
home cages, given an intraperitoneal (i.p.) ethanol or equivolume saline injection according
to the dosing schedule outlined in Table 2.1, and were placed into the center of an open-field
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arena that automatically recorded activity via photo beam breaks (Harvard Apparatus, Inc.,
Holliston, MA). The open field arena measured 40.64 cm by 40.64 cm by 30.48 cm and was
made of clear Plexiglas. Several cm of corncob bedding were placed into the open field
chamber to aid in cleaning and to prevent the buildup of odor. Testing sessions were 20-min
in duration and soiled bedding was removed from the chamber after each session. In
summary, mice received three i.p. injections of isotonic saline (one injection per day) every 2
to 3 days to establish a locomotor baseline for activity and to allow the mice to habituate to
the testing procedure. Following completion of baseline testing, mice received i.p. ethanol
injection (one per day) two times a week for up to ten injections. Mice on the 129/SvEv x
C57BL/6J genetic background were given a 1.4 g/kg dose while mice on the C57BL/6J
genetic background were given a 2.0 g/kg dose (20% w/v solutions were mixed in isotonic
saline). Doses of ethanol for each genetic background were chosen based on pilot
observations in our laboratory. Higher doses where shown to have a significant sedative
component. After ethanol injections, mice were tested following a single (129/SvEv x
C57BL/6J mice) or two (C57BL/6J mice) i.p. saline injections (one injection per day) to
examine specificity of the effects of ethanol on locomotor activity. Mice on the C57BL/6J
genetic background received two additional ethanol tests immediately after saline injections.
Finally, as an additional test for specificity of the effects of ethanol injection on locomotor
activity, naïve RII-/- (male, n = 10; female, n = 10) and RII+/+ (male, n = 10; female, n =
10) mice on the mixed 129/SvEv x C57BL/6J background were run in a study using
procedures similar to those described above with the exception that only i.p. saline injections
were given over 8 trials.
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To determine blood ethanol levels, 6 µl tail nick blood samples were taken from
129/SvEv x C57BL/6J mice immediately after the 1st, 5th, and 10th 20-min test sessions that
were run on ethanol injection days. For C57BL/6J mice, blood samples were collected
following the 20-min session on the last (twelfth) ethanol injection day. Procedures for
assessing blood ethanol levels are described below.
Ethanol-Induced Locomotor Activation: Home-cage Injections
Drug-naïve RII-/- (male, n = 10; female, n = 10) and RII+/+ (male, n = 10; female, n = 10)
mice on a pure C57BL/6J background were tested during the light phase of their light:dark
cycle. An overview of the sensitization paradigm, adapted from (Lessov et al. 2001), is
described in Table 2.2. This paradigm was used for its ability to induce locomotor
sensitization in wildtype C57BL/6 mice. On test day 1-3, all mice received i.p. injections of
isotonic saline (one injection per day) based on the equivalent volume for a 2.0 g/kg ethanol
injection prior to being placed into the center of the open-field arena for 20-min sessions. On
day 4, all mice received an i.p. injection of 2.0 g/kg ethanol prior to placement in the
locomotor chamber in order to determine basal ethanol responsiveness during the 20-min
session. Mice were then assigned to treatment groups equated for locomotor activity during
the initial ethanol response (Day 4). Over the next ten days, mice received daily i.p.
injections of 2.5 g/kg ethanol and were immediately returned to their home cage. On day 15,
half of the mice received an i.p. injection of 2.0 g/kg ethanol and were immediately placed
into the center of the activity apparatus to assess ethanol-induced locomotor sensitization.
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The remaining mice received an i.p. injection of saline to test for general activity not
attributable to ethanol.
Blood Ethanol Concentrations
6 µl tail nick blood samples were collected into capillary tubes and dispensed into 12x75 mm
borosilicate glass tubes containing 375 µl of water and 0.5 g of NaCl. These liquid samples
were capped and refrigerated until processing by gas chromatography. Liquid ethanol
standards (also 6 µl, 0-200 mg%) and samples were similarly prepared and heated in a water
bath at 55 °C for 10 min. Subsequently, a 1.5 ml sample of headspace gas was removed from
the glass tubes with a plastic 3.0 ml syringe and injected directly into a SRI 8610C gas
chromatograph (Torrance, CA) equipped with an external syringe adapter and 1.0 ml external
loading loop. Samples were run at 140°C through a Hayesep D column and detected with
FID at approximately 2 min post-inject. Hydrogen gas, carrier gas (also hydrogen), and
internal air generator flow rates were 13.3, 25, and 250 ml/min, respectively. Areas under the
curve for blood samples were analyzed with SRI PeakSimple software for Windows running
on a Dell Inspiron 3500 ® laptop computer and converted to mg% in blood based on the
curve generated for the standards.
Data Analyses
As a measure of the stimulant effects of ethanol on locomotor activity, the data for each
ethanol test day data was expressed as change from average saline baseline (activity
following ethanol injection – daily average of activity following initial saline injections). As
a measure of sensitization to the effects of ethanol on locomotor activity, locomotor activity
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on the first ethanol test day was subtracted from each of the subsequent ethanol test day data
points (activity following the second and subsequent ethanol injection – activity following
the first ethanol injection). Locomotor activity data (raw and converted) were analyzed using
analyses of variance (ANOVA). All data are presented as mean + S.E.M. and t-tests were
used for planned comparisons (Winer et al. 1991). Significance was accepted at P < 0.05
(two-tailed).
Results
Ethanol-Induced Locomotor Sensitization: Test Chamber Injections
Locomotor activity data from mice maintained on the 129/SvEv x C57BL/6J are presented in
Fig. 2.1. There were no differences between genotypes in locomotor activity following
baseline saline injections or the saline injection given after the ethanol test days as
determined by non-significant ANOVAs (Fig. 2.1A). Interestingly, the RII-/- mice showed
significantly greater locomotor activity over the 10 days of ethanol injections. A repeated
measures ANOVA performed on ethanol-induced locomotor activity data revealed a
significant main effect of genotype [F(1, 51) = 7.18, p = .01]. Post hoc tests indicated that the
RII-/- mice were significantly more active on ethanol injection days 1, 2, 4, 5, 6, 9, and 10
relative to RII+/+ mice. Similarly, when locomotor activity data were expressed as change
from baseline activity (Fig. 2.1B), a repeated measures ANOVA run on ethanol test days
showed a significant genotype main effect [F(1, 51) = 6.88, p < .05] and post hoc tests
indicated greater locomotor activity by RII-/- mice on days 2, 4, 6, 9, and 10. There were no
genotype differences during the final saline injection. Surprisingly, when locomotor activity
data were expressed as change relative to activity following the first ethanol injection - the
assessment of locomotor sensitization (Fig. 2.1C), ANOVAs revealed no significant
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genotype differences during ethanol test days or during the final saline injection. Taken
together, these data suggest that while RII-/- mice on the mixed 129/SvEv x C57BL/6J
genetic background were more sensitive to the stimulant effects of ethanol relative to RII+/+
mice (Fig. 2.1A and B), there were no genotype differences in the development of behavioral
sensitization (Fig. 2.1C). Fig. 2.2 shows blood ethanol levels following the 1st, 5th, and 10th
days of ethanol testing. Repeated measures ANOVA revealed no significant genotype or day
effects. Thus, differences in ethanol-induced locomotor activity between RII-/- and RII+/+
mice are not associated with altered blood ethanol levels. Importantly, RII-/- and RII+/+
mice on the mixed 129/SvEv x C57BL/6J genetic background did not differ in locomotor
activity following 8 days (3 baseline days, averaged; 5 test days) of saline injection (Fig.
2.3).
Locomotor activity data from mice maintained on the C57BL/6J are presented in Fig.
2.4. ANOVA of average baseline locomotor activity following the initial saline injections
revealed that relative to the RII-/- mice, RII+/+ mice showed greater locomotor activity (Fig.
2.4A) [F(1, 51) = 5.627, p < .05]. However, there were no significant differences in
locomotor activity following saline injections given between the 10th and 11th ethanol
injection (as noted as S4 and S5 in Figure 2.4A). These injections were conducted to
demonstrate the specificity of the locomotor response. Despite showing lower basal
locomotor activity, RII-/- mice on the C57BL/6J genetic background showed significantly
greater ethanol-induced locomotor activity as revealed by a significant genotype main effect
following a repeated measures ANOVA run on the first 10 days of ethanol testing [F(1, 47) =
23.86, p < .001]. Post hoc tests indicated that RII-/- mice were significantly more active at
each of the 10 days. Similarly, a repeated measures ANOVA run on ethanol tests days 11 and
18
12 showed a significant main effect of genotype [F(1, 48) = 24.088, p < .001] that reflected
the increased activity of RII-/- mice relative to wild-type animals. When expressed as change
from baseline activity (Fig. 4B), repeated measures ANOVAs revealed genotype differences
during the initial 10 ethanol injections [F(1, 47) = 30.368, p < .001] and during the two
ethanol injections given at the end of the study [F(1, 48) = 33.281, p < .001]. Post hoc tests
indicated that RII-/- mice showed greater locomotor activity relative to RII+/+ mice at every
ethanol test day. There were no genotype differences in change from baseline data following
saline injections (S4 and S5). In general, the overall pattern of data in Fig. 2.4B indicates that
RII-/- mice are more sensitive to the stimulant effects of ethanol. However, it is important to
note that following the first ethanol injection, both RII-/- and RII+/+ mice showed reduced
activity relative to baseline activity. Significant genotype differences at this point are
consistent with previous observations indicating that RII-/- mice are less sensitive to the
sedative properties of ethanol (Fee et al. 2004; Thiele et al. 2000b).
C57BL/6J locomotor data expressed as change relative to the first ethanol injection
are shown in Fig. 2.4C. In contrast to the mixed background mice, C57BL/6J RII-/- mice
exhibited significantly greater expression of ethanol-induced locomotor sensitization over the
course of ethanol injections. This conclusion was supported by a repeated measure ANOVA
that revealed a significant main effect of genotype [F(1, 47) = 13.428, p = .001]. Post hoc
analyses showed significant genotype differences on ethanol test days 4-10, 11, and 12.
Additionally, a repeated measures ANOVA run on the final two ethanol test days was
significant ([F(1, 49) = 11.674, p = .001]), again indicating that RII-/- mice showed greater
expression of locomotor sensitization relative to RII+/+ mice. On the other hand, a genotype
main effect following a repeated measures ANOVA revealed that RII+/+ mice showed
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significantly greater locomotor activity relative to RII-/- mice following saline injections (S4
and S5) [F(1, 49) = 18.415, p < .001]. Finally, there were no significant differences between
RII-/- (219.20 + 6.59 mg%) or RII+/+ (217.27 + 6.18 mg%) mice in blood ethanol levels
immediately following the last ethanol test session on day 12. Thus, similar to mice on the
mixed genetic background, RII-/- mice in the pure C57BL/6J genetic background were more
sensitive to the stimulant effect of ethanol relative to RII+/+ mice (Figs. 2.4A and B).
Additionally, the greater increases in ethanol-induced locomotor activity by RII-/- mice
following repeated ethanol injections (Fig. 2.4C) indicated that RII-/- mice on the C57BL/6J
genetic background were also more sensitive to the development of locomotor sensitization.
Ethanol-Induced Locomotor Activation: Home Cage Injections
Locomotor activity data following home cage ethanol injections in mice maintained on a
C57BL/6J genetic background are presented in Fig. 2.5. Similar to the previous experiment,
RII-/- mice on the C57BL/6J genetic background showed less average locomotor activity
following baseline saline injections (Fig. 2.5A), as evidenced by a significant ANOVA [F(1,
38) = 5.685, p < .05]. Furthermore, an ANOVA run on locomotor data collected following
the first ethanol injection (day 4) revealed that RII-/- mice showed significantly greater
activity relative to RII+/+ mice [F(1, 38) = 9.311, p < .005]. A two-way mixed factor
ANOVA run on locomotor activity data from test day 15 showed significant main effects of
drug [F(1, 36) = 97.204, p < .001] and genotype [F(1, 36) = 7.681, p < .01], and a significant
interaction between these variables [F(1, 36) = 5.245, p < .05]. Post hoc tests indicated that
while locomotor activity was enhanced by ethanol injection (relative to saline injection) in
both genotypes, such increases were greater in RII-/- mice.
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Test day activity data expressed as change from average baseline are presented in Fig.
2.5B. A two-way mixed factor ANOVA revealed significant genotype [F(1, 36) = 18.135, p
< .001] and drug treatment [F(1, 36) = 106.113, p < .001] main effects. Post hoc tests
confirmed that RII-/- mice show greater ethanol-induced increases, and less saline-induced
decreases, in locomotor activity relative to RII+/+ mice. Test day activity data expressed as
change from first ethanol injection are presented in Fig. 2.5C. A two-way mixed factor
ANOVA revealed a significant treatment main effect [F(1, 36) = 90.7, p < .001], but the
genotype main effect was not significant. Additionally, the interaction effect was significant
[F(1, 36) = 5.012, p < .05]. Post hoc analyses revealed that this interaction could not be
attributed to significant differences in locomotor activity in saline or ethanol treated RII-/- 
and RII+/+ mice. Taken together, these data indicate that with the home cage injection
paradigm, RII-/- mice on the C57BL/6J genetic background are more sensitive to the
locomotor stimulant effects of ethanol (Fig. 2.5B) but did not show enhanced sensitivity to
behavioral sensitization (Fig. 2.5C) when compared with RII+/+ mice in this paradigm.
Discussion
In the present report, RII-/- mice consistently showed significantly greater ethanol-
induced locomotor activity relative to RII+/+ mice. RII-/- mice also showed increased
sensitivity to ethanol-induced locomotor sensitization, an effect that may be dependent on
genetic background and/or testing paradigm. Importantly, increased locomotor activity by
RII-/- mice was specific to ethanol injections (and not seen following saline injections), and
was not associated with altered blood ethanol levels. Normal blood ethanol levels and ethanol
metabolism by RII-/- mice has previously been documented (Fee et al. 2004; Thiele et al.
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2000b). Since RII-/- mice show blunted PKA activity in critical brain regions, such as the
striatum and nucleus accumbens (Brandon et al. 1998; Thiele et al. 2000b), the present
results suggest that normal PKA signaling is part of a mechanism that protects against
ethanol-induced locomotor activity and behavioral sensitization.
A growing body of literature is emerging indicating that phenotypes, including
neurobiological responses to ethanol, can depend on the genetic background of the knockout
model (Bowers et al. 1999; Howe et al. 2002; Kelly et al. 1998; Palmer et al. 2003; Phillips et
al. 1999; Simpson et al. 1997; Thiele et al. 2000a). It is possible that the protective role of the
RII subunit of PKA against ethanol-induced behavioral sensitization depends on epistatic
interactions with other genes, interactions that may depend on the genetic background of the
mouse. This argument is consistent with the observation in the present report that RII-/- mice
on the pure C57BL/6J, but not the mixed 129/SvEv x C57BL/6J, genetic background showed
enhanced behavioral sensitization when repeated ethanol injections where given immediately
before locomotor activity testing. Alternatively, the expression of enhanced behavioral
sensitization by RII-/- mice may have depended on procedural differences between
experiments, rather than mouse genetic background. In fact, different sensitizing doses of
ethanol were used in each of the three experiments reported here, ranging from a 1.4 to a 2.5
g/kg dose. In addition, C57BL/6J RII-/- mice were given repeated ethanol injections either
just before locomotor activity testing or in their homecage environment. Recent work has
documented that the expression of phenotypes in mouse research can be sensitive to subtle
differences in the testing procedures as well as the testing environment (Boehm et al. 2000;
Crabbe et al. 1999; Rustay et al. 2003). Taken together, while the role of the RII subunit of
PKA in ethanol-induced behavioral sensitization may depend on mouse genetic background
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(and thus epistatic interactions between genes), it is also possible that different outcomes
between experiments resulted from procedural differences.
With the use of RII-/- mice, the present results are the first direct demonstration that
normal PKA signaling is protective against the stimulant effects of ethanol and ethanol-
induced behavioral sensitization. This being said, caution is necessary when drawing
conclusions because it is becoming increasing clear that interpretations of phenotypic data
from studies with knockout mice are subject to several caveats (Gerlai 2001). One concern is
that constitutive deletion of a gene could lead to compensatory processes (up or down
regulation of other genes) during development. In fact, the relative distribution of other
regulatory subunits up-regulate in an apparent attempt to compensate for the loss of RII in
the present model (Amieux et al. 1997; Brandon et al. 1998). However, it stands to reason
that this compensation is not complete as evidenced by reduced cAMP-stimulated PKA
activity in brain regions such as the striatum, nucleus accumbens, amygdala, hippocampus
and hypothalamus (Brandon et al. 1998). A second concern pertaining to knockout models,
as noted above, is the possibility that there are epistatic interactions between genes such that
observed phenotypes may be dependent on the genetic background of the mouse. One way to
address this concern is to test the knockout model on at least two genetic backgrounds as we
have done in this report. While increased sensitivity to ethanol-induced behavioral
sensitization may depend on the genetic background of RII-/- mice, increased sensitivity to
ethanol-induced locomotor activity was observed in RII-/- mice on both genetic backgrounds
tested. A third concern is that differences between knockout and wild-type mice may be
related to genes other than the mutated gene, a problem that is exacerbated when mice are
maintained on a hybrid genetic background (i.e., 129/SvEv x C57BL6J). One solution that
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has been proposed to address this issue is to test mice that have been backcrossed to one
genetic background. Here, we studied RII-/- mice that were backcrossed to a C57BL/6J
background over 8 generations.
We have previously shown that deletion of the RII subunit results in a mouse that
will more readily consume ethanol solutions compared to wildtype littermate controls in the
absence of altered taste preference, caloric intake, or ethanol metabolism (Fee et al. 2004;
Thiele et al. 2000b). Recently, we found that increased ethanol consumption by RII-/- mice
is not reliably predicted by basal levels of anxiety (Fee et al., 2004) despite the observation
that blunted PKA activity and phosphorylated CREB (pCREB) in the amygdala are
associated with increased anxiety-like behavior (Pandey et al. 2003). In addition to drinking
more ethanol and showing increased sensitivity to the stimulant effects of ethanol, the RII-/- 
mice consistently show reduced sensitivity to the sedative properties of ethanol (Fee et al.
2004; Thiele et al. 2000b) and in the present report RII-/- mice were resistant to the sedative
effects of an initial ethanol injection on locomotor activity that was evident in RII+/+ mice
(Figs. 2.1A, 2.4A and B, and 2.5A). This latter observation raises the possibility that
increased sensitivity to ethanol-induced locomotor stimulation and sensitization by RII-/- 
mice are perhaps secondary to reduced sensitivity to the sedative effects of ethanol. While
this issue cannot be completely ruled out, Phillips and colleagues have consistently
demonstrated a dissociation between tolerance to the sedative/ataxic effects of ethanol and
ethanol-induced behavioral sensitization (Meyer and Phillips 2003; Phillips et al. 1996).
Furthermore, RII-/- mice show enhanced behavioral sensitization to amphetamine (Brandon
et al. 1998), a drug that does not induce sedation.
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It has been suggested that increased sensitivity to the stimulant effects of drugs and
behavioral sensitization that develops following repeated drug exposure may be an
underlying common mechanism that increases the risk for developing drug dependence
(Robinson and Berridge 1993; 2000; 2001). Consistent with this relationship, ethanol-
preferring C57BL/6J mice showed increased ethanol preference after the acquisition of
behavioral sensitization (Lessov et al. 2001) and a study with selectively bred high alcohol
preferring (HAP) and low alcohol preferring (LAP) mice found that high ethanol preference
was predictive of the acquisition of ethanol-induced locomotor sensitization (Grahame et al.
2000). Other manipulations of protein expression in mice have suggested a connection
between ethanol preference and the development of locomotor sensitization following
repeated ethanol injections (Szumlinski et al. 2005a). Here we extend these findings by
showing a positive correlation between ethanol preference and ethanol-induced behavioral
sensitization in the RII-/- mouse model. At odds with this theoretical perspective is the
observation that the DBA/2J strain of mice readily acquires ethanol-induced behavioral
sensitization but strongly avoids consuming ethanol (Lessov et al. 2001; Phillips et al. 1994).
However, a recent study by Camarini and Hodge found that repeated ethanol injections in
DBA/2J mice significantly increased ethanol intake to levels similar to that observed in
C57BL/6 mice (Camarini and Hodge 2004).
While the present results are the first direct demonstration that PKA signaling
modulates the stimulant effects of ethanol and ethanol-induced behavioral sensitization,
previous pharmacological and genetic studies have established that PKA signaling is
involved with amphetamine- (Crawford et al. 2004; Crawford et al. 2000; Tolliver et al.
1999) and cocaine- (Miserendino and Nestler 1995; Park et al. 2000; Schroeder et al. 2004)
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induced locomotor sensitization. Of direct relevance to the present report is the observation
that RII-/- mice are more susceptible to the acquisition of locomotor sensitization following
repeated amphetamine exposure (Brandon et al. 1998). Interestingly, repeated amphetamine
exposure reduces PKA activity in the nucleus accumbens and striatum (Crawford et al. 2004;
Crawford et al. 2000). Thus, we speculate that reduced PKA signaling in these regions causes
RII-/- mice to be more sensitive to the stimulant effects of ethanol as well as ethanol- and
amphetamine-induced behavioral sensitization. Because dynorphin, a neuropeptide that is
reduced in the dorsal medial striatum of RII-/- mice (Brandon et al. 1998), plays an
inhibitory role in sensitization (Heidbreder et al. 1995), it can be speculated that increased
ethanol- and amphetamine-induced behavioral sensitization in RII-/- mice may be the result
of low striatal dynorphin activity. However, we suggest that a degree of caution is necessary
in that it is still unclear to what extent, if any, the neuronal mechanisms involved in ethanol-
and amphetamine-induced locomotor sensitization overlap.
Collectively, these data provide the first direct evidence that normal PKA signaling,
and specifically the RII subunit of PKA, plays a protective role against the stimulant effects
of ethanol and ethanol-induced behavioral sensitization. Future studies are required to define
the specific brain regions in which PKA signaling influences behavioral sensitization and
whether PKA signaling influences this phenomenon by affecting pre- and/or post-synaptic
neuronal function.
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Table 2.1 - Dosing schedule for ethanol-induced locomotor activity: test chamber
injections.
129/SvEv x C57BL/6J
Test Day 1-3 Test Day 4-13 Test Day 14
Equivolume
I.p. Saline
1.4 g/kg
I.p. Ethanol
Equivolume
I.p. Saline
C57BL/6J
Test Day 1-3 
 
Test Day 4-13 Test Day 14-15 Test Day 16-17
Equivolume
I.p. Saline
2.0 g/kg
I.p. Ethanol
Equivolume
I.p. Saline
2.0 g/kg
I.p. Ethanol
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Table 2.2 - Dosing schedule for ethanol-induced locomotor activity: home cage injections.
Treatment Day 1-3 Day 4 Day 5-14 Day 15
Group Habituation Initial Ethanol Conditioning Test Day
EtOH Saline - LC 2.0 EtOH - LC 2.5 EtOH - HC 2.0 EtOH - LC
Saline Saline - LC 2.0 EtOH - LC 2.5 EtOH - HC Saline - LC
LC = Locomotor Chamber, HC = Home Cage
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Figure 2.1 Acquisition test for ethanol-induced locomotor activation and sensitization
in129/SvEv x C57BL/6J RII-/- and RII+/+ mice. (A) represents raw data for locomotor
activity during a 20-minute activity session. Average baseline constitutes the numerical
average for activity during the three habituation sessions. (B) represents locomotor activity
corrected for basal activity (Ethanol trial activity 1-10 minus average baseline activity). (C)
represents the acquisition of locomotor sensitization by presenting each ethanol exposure
corrected for baseline ethanol exposure (Ethanol trial 2-10 minus Ethanol trial 1 activity). All
values reported are mean + SEM. There were significant genotype differences in ethanol-
induced locomotor activity but not in ethanol-induced sensitization.
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Figure 2.2 Blood ethanol concentrations (mg%) in 129/SvEv x C57BL/6J RII-/- and RII+/+
mice. Immediately following ethanol test sessions 1, 5, and 10, 129/SvEv x C57BL/6J RII-/- 
and RII+/+ mice had tail blood collected for analysis using gas chromatography to assess the
possibility of alterations in ethanol pharmacokinetics over the course of the study. All values
reported are mean + SEM. There were no significant genotype differences.
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Figure 2.3 Locomotor activation and sensitization in129/SvEv x C57BL/6J RII-/- and
RII+/+ mice following repeated saline injections. (A) represents raw data for locomotor
activity during a 20-minute activity session following saline injection equivalent in volume to
a 1.4 g/kg ethanol injection. Average baseline constitutes the average activity for all three
habituation sessions. (B) represents locomotor activity corrected for basal activity (Saline
trial activity 1-5 minus average baseline activity). All values reported are mean + SEM.
There were no significant genotype differences in saline-induced locomotor activity.
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Figure 2.4 Acquisition test for ethanol-induced locomotor activation and sensitization in
RII-/- and RII+/+ mice maintained on a C57BL/6J background. (A) represents raw data for
locomotor activity during a 20-minute activity session. Average baseline constitutes the
numerical average for activity during the three habituation sessions. (B) represents
locomotor activity corrected for basal activity (Ethanol trial activity 1-10,ethanol trial 11+12,
and saline trial 4+5 minus average baseline activity). (C) represents the acquisition of
locomotor sensitization by presenting each ethanol exposure corrected for baseline ethanol
exposure (Ethanol trial activity 2-10,ethanol trial 11+12, and saline trial 4+5 minus Ethanol
trial 1 activity). All values reported are mean + SEM. There were significant genotype
differences in ethanol-induced locomotor activity and ethanol-induced locomotor
sensitization.
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Figure 2.5 Expression test for ethanol-induced locomotor activation and sensitization in
RII-/- and RII+/+ mice maintained on a C57BL/6J background. (A) represents raw data for
locomotor activity during a 20-minute activity session following first ethanol exposure
(Ethanol Day 4) in locomotor chamber and final ethanol exposure (Ethanol Day 15). On days
5-14 ethanol was administered in the home cage and mice were not exposed to the locomotor
chamber. Average baseline constitutes the numerical average for activity during the three
habituation sessions. (B) represents locomotor activity on Day 15 corrected for basal activity
(Ethanol Day 15 activity minus average baseline activity). (C) represents the acquisition of
locomotor sensitization by presenting final ethanol exposure corrected for baseline ethanol
activity (Ethanol Day 15 activity minus Ethanol Day 4 activity). All values reported are mean
+ SEM. There were significant genotype differences in ethanol-induced locomotor activity
but not ethanol-induced locomotor sensitization.
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CHAPTER 3 
EXPERIMENT 2: RESTRAINT STRESS-INDUCED CROSS-SENSITIZED 
RESPONSE TO ETHANOL: POSSIBLE CONTRIBUTION OF PROTEIN 
KINASE A SIGNALING AND CRF1R RECEPTOR ACTIVITY 
 
Introduction 
Behavioral sensitization is defined as the long-lasting and progressive enhancement 
of the locomotor and motivational responses to a drug following repeated administration 
(Kalivas and Stewart 1991). It is important to note that behavioral sensitization is a 
phenomenon that is not confined to any one particular class of drugs. The idea that sensitized 
responses to different drugs might involve similar mechanisms has been tested over the past 
decades creating more questions than answers. If overlapping mechanisms are indeed 
involved, then sensitization to one drug should confer enhanced sensitivity, or cross-
sensitivity, to other drugs of abuse. Repeated treatment with morphine or cocaine induces a 
hypersensitive locomotor response to ethanol in mice (Lessov and Phillips 2003). It is of 
interest to note that mice repeatedly injected with ethanol did not show a similarly cross-
sensitized response to morphine or cocaine (Lessov and Phillips 2003). A cross-sensitized 
response to cocaine is possible in ethanol-treated mice if exposure to testing chamber is kept 
to a minimum (Itzhak and Martin 1999). Repeated treatment with nicotine has also been 
shown to produce a cross-sensitized response to ethanol; an effect mediated by calcium 
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channel antagonists (Biala and Weglinska 2004). Genetic approaches have also proven useful 
in understanding mechanisms involved in cross-sensitization. Rats selectively bred for their 
ethanol preference, Alko Alcohol (AA) rats, exhibit behavioral sensitization following 
repeated morphine treatment; an effect that was absent in alcohol avoiding Alko Non-
Alcohol (ANA) rats (Ojanen et al. 2007). Ojanen and colleagues (2007) also found that this 
heighten effect of behavioral sensitization in AA rats was accompanied by increased 
glutamate levels in the ventral tegmental area (VTA) but not in ANA rats. These studies 
suggest that a variety of drugs might share parallel or overlapping mechanisms with respect 
to the expression of locomotor sensitization. Clearly drug history as well as genetic factors 
both can play a role in this phenotype. 
The administration of a varied number of stress models, including restraint stress 
(Roberts et al. 1995), social defeat (Yap et al. 2005), maternal separation (Kikusui et al. 
2005), social isolation (Frances et al. 2000), and variable stress (Lepsch et al. 2005) have 
been shown to cause the acquisition of an enhanced sensitivity to the locomotor stimulatory 
properties of a variety of drugs of abuse.  This stress-induced cross-sensitization is a 
phenomenon of particular interest given the hypothalamic-pituitary-adrenal (HPA) axis 
activation which accompanies the administration of abused drugs. Just as exposure to stress 
leads to a hypersensitive locomotor reaction to drug, cross-sensitization is also possible in the 
opposite direction; in other words, repeated exposure to drug will create a sensitized response 
to stress (Breese et al. 2005; Erb et al. 2003; Levy et al. 1994). These studies suggest the 
possibility that exposure to repeated stresses (or drug) leads to dysregulation of HPA axis 
signaling, which it turn, mediates the behavioral sensitization that accompanies subsequent 
drug exposure. In the human literature, individuals suffering from affective disorders can 
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exhibit a sensitized stress response mediated by activation of the HPA axis (Arborelius et al. 
1999). It stands to reason that dysregulation of HPA axis signaling similar to that seen in 
chronic affective disorders might underlie the hypersensitivity to drug observed in behavioral 
sensitization. Recent rodent studies confirm that a depressant-like behavioral profile is 
associated with enhanced sensitivity to the development of sensitization (Alttoa et al. 2007; 
Wei et al. 2004). 
Taking these findings one step further, investigators have attempted to use 
pharmacological and physiological interventions to gain a better understanding of the 
mechanisms that underlie stress and drug-induced cross-sensitization. There have been many 
promising findings in the literature but a clear and consistent pattern of results has yet to 
emerge. What follows is brief summary of the available literature. In examining a role for 
stress signaling in sensitization, the physiological endpoint, cortisol in humans and 
corticosterone in rodents, is often targeted. Adrenalectomy eliminates the synthesis and 
release of corticosterone, and has been shown to block the acquisition of cocaine 
sensitization if performed prior to the sensitization regime (Przegalinski et al. 2000). In 
contrast, if the sensitization paradigm is initiated prior to adrenalectomy, the expression of 
cocaine sensitization remains intact (Przegalinski et al. 2000).  Prasad and colleagues also 
find a similar inability of adrenalectomy to alter the expression of cocaine-induced locomotor 
sensitization (Prasad et al. 1996). However, it is reported that adrenalectomy blocks the 
acquisition of sensitization when tested in acute withdrawal (24 hrs) but not in late 
withdrawal at 1 week (Prasad et al. 1996). Taken together these studies suggest the 
importance of glucocorticoid signaling in the acquisition of sensitized behaviors.  
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Similarly, administration of the glucocorticoid receptor antagonist, RU38486, prior to 
repeated restraint stress has been shown to block the acquisition of a cross-sensitized 
locomotor response to ethanol (Roberts et al. 1995). These findings point to the level of 
glucocorticoid signaling or receptor binding and activation as being critical to the 
development of behavioral sensitization. This is evidenced by the fact that elimination of 
corticosterone release with adrenalectomy or prevention of glucocorticoid receptor binding 
through pharmacological blockade prevent to the acquisition of a sensitized or cross-
sensitized response. It is important to point out that additional studies have also suggested a 
role for glucocorticoid receptor signaling in the expression of a sensitized response. 
Pretreatment with the glucocorticoid receptor antagonist, mifepristone, blocks the expression 
of a sensitized locomotor response to amphetamine, while the drug had no effect on 
amphetamine responses in drug naïve rats (De Vries et al. 1996). Roberts et al. (1995) also 
found that RU38486 could block the acquisition of ethanol-induced locomotor sensitization 
in mice. Aside from the dissociation between adrenalectomy and receptor blockade, the 
aforementioned studies point to the importance of glucocorticoid signaling in both the 
acquisition and expression of behavioral sensitization.  
Alterations in the activation of the HPA axis upstream of glucocorticoid have also 
been implicated in behavioral sensitization. Intracerebroventricular (i.c.v.) administration of 
the CRF antagonist, D-helical CRF, reduced stereotypic response to amphetamine following 
repeated restraint stress in rats (Cole et al. 1990b). In contrast, an augmentation of HPA axis 
signaling via pharmacological manipulation can result in the expression of sensitized 
behaviors. I.c.v. administration of CRF rather than subcutaneous administration of CRF leads 
to long-term locomotor sensitization to D-amphetamine (Cador et al. 1993). Similarly, 
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microinfusion of CRF into the shell of the nucleus accumbens of rats led to a prolonged 
increase in general locomotor activity (Holahan et al. 1997). It also appears that a blockade 
of endogenous CRF signaling via administration of CRF receptor 1 antagonist, CP-154,526, 
will reduce cocaine-induced locomotor sensitization and relapse behavior (Przegalinski et al. 
2005). These approaches have yielded fruitful results, and further investigation is necessary 
to more fully understand the role of CRF signaling and its effects on HPA axis activity in the 
acquisition and expression of cross-sensitized drug responses. 
The RIIE knockout mouse model has been used to assess the role of protein kinase A 
(PKA) signaling on ethanol self-administration and a variety of other ethanol-related 
phenotypes (Fee et al. 2006; Fee et al. 2004; Thiele et al. 2000b). This is one of several 
genetic models to effectively demonstrate an enhanced sensitivity to drug-induced locomotor 
sensitization (Brandon et al. 1998; Fee et al. 2006; McDougall et al. 2005; Runkorg et al. 
2006; Wei et al. 2004). The RIIE-/- mice represent a unique opportunity to identify a role for 
PKA signaling in the acquisition of a stress-induced cross-sensitized response to ethanol. 
There is considerable evidence in the literature suggesting a role for PKA activity in the 
regulation of HPA axis activity. For example, Vargas and colleagues have suggested that the 
effects of diazepam on HPA axis activity are mediated via cAMP-dependant PKA activity in 
the hypothalamus (Vargas et al. 2001). PKA activity has also been put forward as a potential 
mechanism underlying the diminished hippocampal activity thought to be associated with the 
HPA axis hyperactivity in depression (Perera et al. 2001). Specifically, ethanol has been 
shown to increase PKA and cAMP activity and, in turn, increase CRF peptide secretion (Li et 
al. 2005). Additionally, PKA activity has been shown to play an essential role in CRF 
mediated decreased expression of CRF receptor 1 mRNA in part via the phosphorylation of 
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cAMP response element binding (CREB) (Kasagi et al. 2002). However, other investigators 
have suggested a role for protein kinase C (PKC) and PKA in ACTH release (Iwabuchi et al. 
1999), and a role for G protein receptor kinase (GRK) in the activity of CRF type 1 receptors 
(Dautzenberg et al. 2001). 
The following investigation sets out to use inbred strains of mice to reinforce the 
existing literature which suggests that repeated restraint stress can be used to induce a cross-
sensitized locomotor response to ethanol. This study will also attempt to determine if 
enhanced sensitivity to stress is a factor underlying the previously reported heightened 
sensitivity to ethanol-induced locomotor sensitization observed in the RIIE-/- mouse model 
(Fee et al. 2006). In a final experiment, the CRF receptor 1 antagonist, CP-154,526, will be 
used in an attempt to block the acquisition of restraint stress-induced cross-sensitization to 
ethanol. Taken together, the studies highlighted above will not only strengthen the literature 
suggesting the importance of stress mechanisms in behavioral sensitization, but the RIIE
study will also investigate a possible interaction between PKA signaling and stress in an 
animal model with a demonstrated sensitivity to behavior sensitization. 
 
Methods 
Preparation of CP-154,526 
 CP-154,526 (butyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)- 
7H-pyrrolo[2,3-d]pyrimidin-4-yl]-ethylamine) was generously donated by Pfizer (Groton, 
CT).  CP-154,526 was suspended in a vehicle of 0.5% carboxymethylcellulose (CMC).  CP-
154,526 displays high affinity for the CRF-1 receptor (Ki < 10 nM) and blocks CRF 
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stimulated adenylate cyclase activity in rodent pituitary and cortical membranes (Lundkvist 
et al. 1996; Schulz et al. 1996).   
 
Restraint Stress Application  
Restraint is a common method for inducing stress in rodents. The procedure for the 
administration of restraint stress is very similar to the procedure used by Roberts et al. 
(1995). Mice were individually removed from their home cages and placed into plastic 
cylindrical restraint tubes. These tubes securely hold the mouse in place and prevent turning 
around within the tube. All mice were restrained for a period of 2 hours per each daily 
session. New tubes were used each session. Mice undergoing restraint stress were visually 
isolated from other mice. Additionally, mice were observed throughout the restraint session 
as a safety measure. 
 
Restraint-Stress Cross-Sensitization in Inbred Mice 
40 inbred DBA/2J mice and 40 inbred C57BL/6 mice approximately 3 to 6 months of 
age (Jackson Laboratories, Bar Harbor, ME) were put through the cross-sensitization 
paradigm described below.  All animals are transported to the testing room in their home 
cages and allowed to habituate for at least 35-min prior to testing. A small fan provided 
masking noise in the testing room.  On test day 1-3, all mice received isotonic saline (0.9% 
NaCl) injections based on the equivalent volume for a 1.5 g/kg ethanol injection (20% w/v 
solution) prior to being placed into the center of an open-field arena which automatically 
recorded activity via photo beam breaks (Harvard Apparatus, Inc., Holliston, MA) for each 
of the habituation/basal locomotor activity sessions. The open field arena measures 40.64 cm 
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by 40.64 cm by 30.48 cm and was made of clear Plexiglas. Several cm of corncob bedding 
are placed into the open field chamber to aid in cleaning and to prevent the buildup of odor. 
On day 4, all mice will receive a 1.5 g/kg ethanol injection prior to placement in the 
locomotor chamber in order to determine basal ethanol responsiveness. Mice were then 
assigned to treatment groups equated for locomotor activity during the initial ethanol 
response (Day 4). Mice underwent 10 consecutive days of 2.5 g/kg i.p. ethanol injection or 2 
hr of restraint stress in their home cage. On day 15, half of the mice received a 1.5 g/kg i.p. 
ethanol injection to test for the effect of the respective stressor on ethanol-induced locomotor 
sensitization while the remaining mice received an equivolume i.p. saline injection to test for 
general activity not attributable to ethanol. 
 
Restraint-Stress Cross-Sensitization in RII-/- and RII+/+ Mice 
40 RIIE-/- and RIIE+/+ male and female mice approximately 6 months of age 
maintained on an approximately pure C57BL/6 background were put through the cross-
sensitization paradigm.  All animals are transported to the testing room in their home cages 
and allowed to habituate for at least 35-min prior to testing. A small fan provided masking 
noise in the testing room.  On test day 1-3, all mice received isotonic saline (0.9% NaCl) 
injections based on the equivalent volume for a 1.5 g/kg ethanol injection (20% w/v solution) 
prior to being placed into the center of the open-field arena which automatically recorded 
activity via photo beam breaks (Harvard Apparatus, Inc., Holliston, MA) for each of the 
habituation/basal locomotor activity sessions. On day 4, all mice received a 1.5 g/kg ethanol 
injection prior to placement in the locomotor chamber in order to determine basal ethanol 
responsiveness. Mice were then assigned to treatment groups equated for locomotor activity 
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during the initial ethanol response (Day 4). Next, half the mice underwent 10 consecutive 
days of 2 hr of restraint stress while the remaining mice were weighed daily (no stress) and 
returned to their home cages. On day 15, half of the mice received a 1.5 g/kg i.p. ethanol 
injection to test for the effect of restraint stress on ethanol-induced locomotor sensitization 
while the remaining mice received an equivolume i.p. saline injection to test for general 
activity not attributable to ethanol. On day 16, mice receiving ethanol on day 15 received an 
i.p. saline injection and vice versa. 
 
Effect of CP-154,526 on the Acquisition of Restraint Stress-Induced Cross Sensitization 
60 inbred DBA/2J mice approximately 3 months of age (Jackson Laboratories, Bar 
Harbor, ME) were put through the sensitization paradigm described below. Mice were each 
randomly assigned to one of the various treatment groups (n=10 per group: vehicle + 
Restraint; vehicle + No Restraint; 5 mg/kg CP-154,526 + Restraint; 5 mg/kg CP-154,526 + 
No Restraint; 10 mg/kg CP-154,526 + Restraint; or 10 mg/kg CP-154,526 + No Restraint). 
The doses were selected based on the slow elimination of CP-154,526, t1/2 = 51h, as observed 
in a study of its basic pharmacokinetics (Keller et al. 2002) and attempted to minimize the 
possibility of excessive drug accumulation leading to aversive side effects (Arborelius et al. 
2000a). Mice receiving restraint stress were tested for CP-154,526’s ability to block the 
acquisition of restraint stress-induced cross sensitization while non-specific reductions in 
locomotor activity associated with chronic administration of CP-154,526 were assessed in 
non-restrained mice. On test day 1-10, mice received a pretreatment of CP-154,526 or 
vehicle based on treatment group assignment. Thirty minutes later, mice then received either 
2 hr restraint stress session or no additional treatment. Restrained mice were then returned to 
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their homecages and left undisturbed aside from routine animal husbandry. On test day (day 
11), all animals were transported to the testing room in their home cages and allowed to 
habituate for at least 35-min prior to testing. A small fan provided masking noise in the 
testing room. Mice were then injected with a 1.5 g/kg i.p. ethanol injection prior to being 
placed into the center of the open-field arena for the 20 minute locomotor activity sessions.  
 
Data Analyses 
Locomotor activity data were analyzed using analyses of variance (ANOVA). All data are 
presented as mean + S.E.M. and t-tests were used for planned comparisons when applicable 
(Winer et al. 1991). Significance was accepted at P < 0.05 (two-tailed). For all experiments 
presented in this study, locomotor data was collect and analyzed for all 20 minute sessions in 
5 minute bins. Further analysis reveled that the effect of CP-154,526 on locomotor 
sensitization, when present, occurred in the first 5 minute bin of locomotor activity. For this 
reason, only the data from this first bin will be presented in studies using CP-154,526. 
 
Results 
Restraint-Stress Cross-Sensitization in Inbred Mice 
DBA/2J inbred mice show a robust sensitized response to ethanol following either 10 
days of home cage 2.5 g/kg ethanol injections or 2 hrs of restraint stress (Figure 3.1).  A two-
way (treatment (restraint or no stress) X test day drug (ethanol or saline)) ANOVA revealed a 
significant main effect of test day drug [F(1, 36) = 43.223, p < .001] and non-significant 
main effect of treatment as well as a non-significant interaction between the two variables of 
interest. These data suggest that both DBA/2J mice receiving chronic restraint stress and 
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ethanol treatment both show a sensitized response to ethanol but not saline. Similar results 
were also observed in C57BL/6J inbred mice (Figure 3.2).  A two-way (treatment (restraint 
or no stress) X test day drug (ethanol or saline)) ANOVA revealed a significant main effect 
of test day drug [F(1, 36) = 27.568, p < .001] and non-significant main effect of treatment. It 
is of interest to note there existed a significant treatment by test day drug interaction in 
C57/BL/6J mice, [F(1, 36) = 6.369, p < .05]. This effect appears to be attributable to the 
relative differences in the locomotor effects between saline and ethanol-treated mice in the 
restraint treatment groups. 
 
Restraint-Stress Cross-Sensitization in RII-/- and RII+/+ Mice 
RIIE-/- and RIIE+/+ mice exposed to chronic restraint stress show an enhanced 
locomotor response following ethanol injection when compared to RIIE-/- and RIIE+/+ mice 
which received daily handling without restraint (Figure 3.3) for the first 5 min following 
ethanol injection. A two-way (genotype X treatment) ANOVA revealed a main effect of 
genotype [F(1, 36) = 5.431, p < .05] and treatment [F(1, 36) = 5.418, p < .05] but the 
genotype by treatment interaction failed to achieve significance. These data suggest that in 
general RIIE-/- mice were more active following ethanol injection compared to their littermate 
wildtype controls. Additionally, mice of both genotypes receiving restraint stress displayed 
an enhanced response to ethanol compared to daily handled mice but this effect was not 
genotype specific. 
 
CP-154,526 and Acquisition of Restraint Stress-Induced Cross Sensitization 
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Treatment with CP-154,526 prior to exposure to restraint stress failed to attenuate the 
increased locomotor activation that existed in restraint stress treated mice in comparison to 
non-restrained mice. A two way (treatment (restraint or no restraint) X dose (Vehicle, 5 and 
10mg/kg)) ANOVA revealed a significant main effect of treatment [F(1, 54) = 7.929, p < 
.01] but not dose. The treatment by dose interaction also failed to achieve significance 
suggesting that neither dose of CP-154,526 altered the heightened locomotor response in 
restraint stress-treated mice (Figure 3.4). 
 
Discussion 
In the present report, the RIIE knockout mouse model was utilized to determine if 
enhanced sensitivity to stress was a factor contributing to the expression of heightened 
sensitivity to ethanol-induced locomotor activation in these mice. A commonly employed 
restraint stress cross-sensitization paradigm was employed which has been previously 
demonstrated to produce a cross-sensitized locomotor response to ethanol in both our hands 
and other laboratories. RIIE-/- mice failed to show a heightened sensitivity to the effects of 
restraint stress on the cross-sensitized locomotor response to ethanol. Chronic restraint stress 
induced a sensitized response to ethanol compared to non-stressed controls in both RIIE-/- and 
RIIE+/+ mice with no genotype differences in the magnitude of this response. The ability of 
chronic exposure to restraint stress to induce a cross-sensitized response to ethanol was 
demonstrated in two commercially available inbred strains of mice, C57BL/6J and DBA/2J, 
further reinforcing the literature. In an attempt to discern a mechanism for the contribution of 
stress exposure to a cross-sensitized response to ethanol, pretreatment with CRF Receptor 1 
antagonist, CP-154,526, prior to restraint stress sessions in male DBA/2J mice was employed 
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in an attempt to block the acquisition of cross-sensitization. Ultimately this approach was 
ineffective in blocking the acquisition of restraint stress-induced cross-sensitization; an effect 
that was unexpected given the efficacy of the glucocorticoid receptor antagonist, RU38486, 
in this aim (Roberts et al. 1995).  
These data add to a rather small existing literature suggesting that repeated exposure 
to stress, specifically restraint stress, leads to a hypersensitive locomotor response to ethanol 
(Roberts et al. 1995). In a more general sense, these findings join a variety of empirical 
results suggesting that restraint stress exposure, both acute and chronic, lead to a cross-
sensitization to a variety of drugs of abuse including cocaine (Lepsch et al. 2005), 
amphetamine (Badiani et al. 1992; Diaz-Otanez et al. 1997; Pacchioni et al. 2002), and 
morphine (del Rosario et al. 2002). These findings suggest the possibility that exposure to 
repeated restraint stress brings about alterations which ultimately confer a vulnerability to the 
abuse potential for a variety of drugs of abuse. However, a study by Haile and colleagues 
suggests that the predictability of the stressor is of ultimate importance in assessing its ability 
to produce a cross-sensitized response. Ten days of chronic unpredictable stress but not 
chronic predictable stress (restraint) led to a hypersensitive locomotor response to cocaine; an 
effect marked by enhanced corticosterone levels (Haile et al. 2001). The discrepancy between 
the aforementioned study and those previously cited suggest the possibility that any number 
of subtle environmental factors can ultimately contribute to a cross-sensitized response when 
restraint stress is the sensitizing agent.  
 Administration of a glucocorticoid antagonist, RU38486, prior to 10 daily 
administrations of 2-hr restraint stress has been shown to effectively block the acquisition of 
a cross-sensitized response to a 1.5 g/kg i.p. ethanol injection (Roberts et al. 1995). In the 
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present study, substitution of a CRF Receptor 1 antagonist, CP-154,526, for the 
glucocorticoid antagonist failed to have the same effect in DBA/2J mice. It is possible that 
the chosen dose range of CP-154,526 to block the acquisition of restraint stress cross-
sensitized response to ethanol was too modest. The possibility remains that a higher dose of 
CP-154,526 could effectively block the acquisition of a cross-sensitized response to ethanol. 
However, higher doses were avoided based on the long half-life of CP-154,526 which has 
been previously published (Keller et al. 2002). Additionally, osmotic mini-pump treatment 
with a 32mg/kg/day dose led to visible malaise in rats and led to uninterpretable data in a 
previous study (Arborelius et al. 2000a). Doses were chosen that had been shown to produce 
anxiolytic effects but minimized the possibility that daily treatment would lead to drug 
accumulation and a similar malaise. As a possible explanation for lack of effect observed, it 
is interesting to note that chronic treatment (10 day) with an alternate CRF Receptor 1 
antagonist, CRA1000, has been shown to have little effect on plasma concentrations of 
adrenocorticotropic hormone (ACTH) or corticosterone compared to vehicle treated rats at 
baseline and following acute immobilization stress when testing was done 26 hrs following 
the last CRA1000 treatment. In contrast, if CRA1000 is administered 2 hrs prior to restraint, 
it will significantly reduce ACTH and corticosterone levels in response to immobilization 
stress (Ohata et al. 2002). These data suggest the importance of the dosing schedule in 
assessing the ability of a CRF type 1 receptor antagonist to influence downstream 
neuroendocrine release. This should be considered in the design of future experiments aimed 
at altering CRF receptor function in the hope of blocking the stress-related contribution to 
sensitization. Using CRA1000 as a guide, it seems possible that CP-154,526 could 
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potentially have very different effects in its ability to block the acquisition verses the 
expression of a sensitized response.  
Although the RIIE study provides an additional example of restraint stress-induced 
hypersensitivity to ethanol, the present study failed to provide a potential mechanism for the 
genotype differences in ethanol and amphetamine-induced locomotor sensitization previously 
reported in this model. Given the hyperactivity and aggression observed during basic 
handling procedures (unpublished observations), enhanced sensitivity to stress was an 
attractive candidate for further investigation. Daily 2 hr restraint stress sessions caused a 
similar level of sensitivity to the locomotor activational effects of ethanol between RIIE-/- and 
RIIE+/+ mice. If one views sensitized responses as an all or none phenomenon, it is possible 
that 2 hrs of restraint stress would not allow for discrimination between genotype, as it has 
been shown to produce sensitization in wildtype inbred C57BL/6 mice. An alternate 
approach calls for the use a sub-threshold dose of restraint stress (either in duration or 
number of days) in hopes of pulling apart genotype differences. Ultimately, it is possible that 
differences in HPA axis function are not responsible for the genotype differences in 
enhanced sensitivity to ethanol and amphetamine-induced locomotor sensitization.  
 Taken together, the present studies reinforce the literature by providing additional 
evidence that repeated exposure to restraint stress can cause a sensitized locomotor response 
to i.p. ethanol administration in mice. This replicated previous findings in DBA/2J mice 
(Roberts et al. 1995) and extended these findings to C57BL/6J mice. Additionally, this effect 
was also demonstrated in RIIE-/- and RIIE+/+ mice maintained on an approximately pure 
C57BL/6J background. Pretreatment with CP-154,526 prior to restraint stress failed to block 
the acquisition of a sensitized locomotor response to ethanol; a finding that is particularly 
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interesting when considered in light of the fact that pretreatment with a glucocorticoid 
receptor antagonist is effective in achieving this aim. It is possible that compensatory 
changes in HPA axis signaling compensate for chronic CRF receptor 1 blockade, while this 
effect is not possible when the target of antagonism is the end result of neuroendocrine 
release as is the case with glucocorticoid antagonists or synthesis inhibitors. In summary, 
chronic restraint stress can produce a cross-sensitized response to ethanol, but the exact 
mechanisms involved in this phenomenon remain elusive. Further investigation of the effects 
of chronic verses acute antagonism of CRF and glucocorticoid receptor function should 
ultimately contribute to a greater understanding of this phenomenon.  
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Figure 3.1 Restraint stress-induced cross-sensitization to ethanol in male DBA/2J mice. This 
figure represents raw data for locomotor activity during 20-minute locomotor sessions. Prior 
to the first three locomotor sessions mice received saline injections. These data were 
averaged (Sal. Avg.) and serve as a measure of basal locomotor activity. Initial locomotor 
responses to 1.5 g/kg ethanol injection are also presented (Initial). Mice then received 10 
days of either 2hr restraint stress of an i.p 2.5 g/kg ethanol injection. On test day, half of the 
mice from each condition received either a 1.5 g/kg ethanol injection or equivolume saline 
(Test Day). All values reported are mean + SEM. Both chronic ethanol injection and restraint 
stress induced a sensitized response to ethanol. This hyperlocomotor effect was not present in 
saline treated mice.  
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Figure 3.2 Restraint stress-induced cross-sensitization to ethanol in male C57BL/6J mice. 
This figure represents raw data for locomotor activity during 20-minute locomotor sessions. 
Prior to the first three locomotor sessions mice received saline injections. These data were 
averaged (Sal. Avg.) and serves as a measure of basal locomotor activity. Initial locomotor 
responses to 1.5 g/kg ethanol injections are also presented (Initial). Mice then received 10 
days of either 2hr restraint stress of an i.p 2.5 g/kg ethanol injection. On test day, half of the 
mice from each condition received either a 1.5 g/kg ethanol injection or equivolume saline 
(Test Day). All values reported are mean + SEM. Both chronic ethanol injection and restraint 
stress induced a sensitized response to ethanol. This hyperlocomotor effect was not present in 
saline treated mice.  
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Figure 3.3 Effects of chronic restraint stress on locomotor responses to ethanol in RIIE-/- and 
RIIE+/+ mice maintained on an approximately pure C57BL/6 background. Mice received 
either 10 days of either restraint stress (Restraint) or daily handling (Handle). Differences in 
restraint stress verses handled mice existed in the first 5 min bin of the 20 min locomotor 
session. In general, RIIE-/- were more active in response to ethanol regardless of treatment 
condition compared to wildtypes. Restraint stress treated mice were significantly more active 
that handled mice regardless of genotype status. All values reported are mean + SEM. 
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Figure 3.4 Effects of pretreatment with CP-154,526 on the acquisition of restraint stress-
induced cross-sensitization to ethanol in male DBA/2J mice. Mice received pretreatment with 
CP-154,525 (Vehicle, 5 and 10mg/kg) prior to 2hr restraint stress or no restraint. One Test 
Day, mice received a 1.5 g/kg ethanol injection prior to placement in the locomotor chamber. 
Mice receiving chronic restraint stress were significantly more active than mice that did not 
receive stress. Pretreatment with CP-154,526 had no effect on the acquisition of cross-
sensitization in animals receiving stress or general locomotor activity in unstressed mice. All 
values reported are mean + SEM. 
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CHAPTER 4
EXPERIMENT 3: CORTICOTROPIN RELEASING FACTOR (CRF)-1 RECEPTOR
ANTAGONIST, CP-154,526, BLOCKS THE EXPRESSION, BUT NOT
ACQUISITION, OF ETHANOL-INDUCED BEHAVIORAL SENSITIZATION
Introduction
Behavioral sensitization is defined as the long-lasting and progressive enhancement
of the locomotor and motivational responses to a drug following repeated administration
(Kalivas and Stewart 1991). Over the past twenty years, many studies have demonstrated the
ability of repeated ethanol exposure to elicit locomotor sensitization in mice (Crabbe et al.
1992; Cunningham and Noble 1992; Lister 1987; Phillips et al. 1995). It has been suggested
that increased sensitivity to behavioral sensitization may be an underlying mechanism that
increases the risk for developing drug dependence. According to this view, repeated exposure
to a drug promotes neural reorganization leading to a hypersensitive state in brain reward
circuitry (Robinson and Berridge 1993; 2000; 2001). To this end, a greater understanding of
the underlying mechanism of behavioral sensitization may reveal the potential to slow or
prevent the move to addiction as well as provide enhanced treatment options in drug-
dependant populations.
Recent studies have done much to expand our understanding of this complex
phenomenon but the neurochemical basis of ethanol-induced sensitization is still not fully
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understood. A multitude of neurotransmitter systems have been implicated in ethanol-
induced locomotor sensitization including dopamine (Broadbent et al. 2005; Palmer et al.
2003), GABA (Broadbent and Harless 1999), opioids (Camarini et al. 2000; Nestby et al.
1997a; Pastor and Aragon 2006), and glutamate (Broadbent et al. 2003; Kotlinska et al. 2006;
Szumlinski et al. 2005b). The aforementioned neurotransmitter systems all involve guanine
nucleotide binding protein-coupled receptors that recruit protein kinase A (PKA) signaling;
an intracellular signaling mechanism which has been implicated in behavioral sensitization.
Reduction of PKA activity via genetic knockout of the regulatory subunit II has been shown
to enhance sensitivity to both ethanol- (Fee et al. 2006) and amphetamine- (Brandon et al.
1998) induced locomotor sensitization in mice. Just as PKA activity represents a potential
modulator underlying drug-induced behavioral sensitization, an organism’s stress response
mediated by the endogenous stress signaling system, or hypothalamic-pituitary-adrenal
(HPA) axis, may represent a similar point of interest.
It has been suggested that individuals suffering from affective disorders can exhibit a
sensitized stress response mediated by activation of the HPA axis (Arborelius et al. 1999).
HPA axis activation also accompanies drug administration and the application of stress
and/or central administration of corticotropin releasing factor (CRF) can induce a hyper-
locomotive response (Lee and Tsai 1989; Lowry and Moore 2006). Given these data, it
stands to reason that a dysregulation of the components of HPA axis signaling similar to that
seen in chronic affective disorders might underlie the hypersensitivity to drug observed in
behavioral sensitization. Recent rodent studies confirm that a depressant -like behavioral
profile is associated with enhanced sensitivity to the development of sensitization (Alttoa et
al. 2007; Wei et al. 2004) Furthermore, it seems unlikely that a sensitized drug response
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could have evolved to the benefit of the organism; a more likely explanation would involve
drugs of abuse usurping endogenous signaling mechanisms leading to dysregulations
contributing to the development of sensitization. Similar dysregulations of CRF signaling
have been shown to be critically important to ethanol self-administration in ethanol-
dependant rats. CRF receptor antagonist, D-Phe-CRF(12-41), blocked excessive ethanol self-
administration in rats made dependant on ethanol via prolonged exposure to ethanol vapor
(Valdez et al. 2002). Taken together, these findings suggest dysregulations in the components
of HPA axis signaling, specifically CRF, are important in the move from drug use to abuse.
Roles for the HPA axis and its associated neuropeptide, CRF, have also been
implicated in sensitized behaviors but greater attention is required to determine the degree to
which these versatile systems contribute to ethanol-induced locomotor sensitization.
Enhanced sensitivity to the locomotor stimulatory properties of a variety of drugs of abuse
has been observed following the administration of an equally varied number of stress models,
including restraint stress (Roberts et al. 1995), social defeat (Yap et al. 2005), maternal
separation (Kikusui et al. 2005), social isolation (Frances et al. 2000), and variable stress
(Lepsch et al. 2005). Taking these findings one step further, investigators have attempted to
block the effect of stress exposure on drug sensitivity and sensitization through the use of
pharmacological interventions. Administration of glucocorticoid receptor antagonists has
been shown to block the acquisition of ethanol-induced locomotor sensitization brought on
by repeated restraint stress in mice (Roberts et al. 1995). Additionally, the
intracerebroventricular (i.c.v.) administration of the CRF antagonist, -helical CRF, reduced
the stereotypic response to amphetamine following repeated restraint stress in rats (Cole et al.
1990b). In contrast, an augmentation of CRF signaling via pharmacological manipulation can
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result in the expression of sensitized behaviors. I.c.v. administration of CRF rather than
subcutaneous administration of CRF leads to long-term locomotor sensitization to D-
amphetamine (Cador et al. 1993). Similarly, microinfusion of CRF into the shell of the
nucleus accumbens of rats led to a prolonged increase in general locomotor activity (Holahan
et al. 1997). These approaches have revealed the ability to modulate the acquisition and
expression of sensitized drug responses via the manipulation of glucocorticoid and CRF
receptor signaling.
CRF is a 41 amino acid neuropeptide that has been shown to play a critical role in the
stress response and modulate a wide-variety of neurobiological responses to ethanol. On the
most basic level, ethanol exposure has been shown to increase CRF release (Rivier et al.
1984; Rivier and Lee 1996). As previously mentioned, CRF has been shown to be
particularly important in the self-administration of ethanol in ethanol-dependant rats (Valdez
et al. 2002). Additional evidence is provided by the ability of CRF receptor 1 (CRF1R)
antagonists (antalarmin, MJL-1-109-2, and R121919) to block excessive ethanol self-
administration following acute withdrawal in this population (Funk et al. 2007). CRF also
plays an important role in the anxiety-like behaviors associated with the cessation of ethanol
use. Exogenous administration of CRF has been shown to potentiate, or sensitize, ethanol
withdrawal in rats (Overstreet et al. 2004). In contrast, administration of the CRA1000, a
CRF1R antagonist, blocks the reductions in social interaction characteristic the anxiety-like
behavior accompanying ethanol-withdrawal (Knapp et al. 2004). Additionally, administration
of CRF1R antagonists, CRA1000 and CP-154,526, during periods of ethanol withdrawal
attenuates reductions in social interaction following subsequent ethanol withdrawals in rats
(Overstreet et al. 2004). It is important to note that reductions in withdrawal induced
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anxiety-like behavior do not appear to be confined to the CRF receptor 1 system as central
administration of the potent CRF receptor 2 agonist, urocortin 3, attenuated withdrawal-
induced increases in anxiety-like behavior as assessed by reduced time spent in the open
arms of the plus maze as well as in heightened ethanol administration in rats (Valdez et al.
2004). The aforementioned examples demonstrate that CRF is intricately involved in all
stages of ethanol exposure and an investigation of CRF’s role in ethanol-induced locomotor
sensitization is a logical extension of these findings.
Here we investigate if CRF1R signaling is involved in the CNS changes underlying
behavioral sensitization brought on by repeated ethanol injection. To our knowledge, there
has been no investigation of the ability of a CRF1R antagonist to diminish the expression or
block the acquisition of ethanol-induced locomotor sensitization. However, there have been
encouraging demonstrations that treatment with CRF1R antagonists (CP-154,526 and
CRA1000) will block the sensitized anxiety-like response that comes with repeated ethanol
withdrawals (Knapp et al. 2004; Overstreet et al. 2004) The following investigation sets out
to determine if use of a CRF receptor 1 antagonist, CP-154,526, can be an effective
pharmacological tool for blocking both the acquisition and expression of ethanol-induced
locomotor sensitization. Taken together the experiments outlined above should not only add
to the growing literature of ethanol-induced locomotor sensitization but also determine the
efficacy of a pharmacological agent in attenuating a sensitized response to ethanol.
Methods
Animals
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Subjects were 130 male DBA/2J mice (Jackson Laboratory, Bar Harbor, ME) obtained at 8
weeks of age and weighing between 20 and 26 grams at the beginning of the experiment.
Mice were individually housed for two weeks with ad libitum access to standard rodent chow
(Teklad, Madison, WI) and water and maintained at 22°C on a 12h:12h light:dark cycle. All
experiments were conducted in compliance with the National Institutes of Health guidelines
and protocols were approved by the University of North Carolina Animal Care and Use
Committee.
Drug Preparation
CP-154,526 (butyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-
7H-pyrrolo[2,3-d]pyrimidin-4-yl]-ethylamine) was donated by Pfizer (Groton, CT), and was
suspended in a vehicle of 0.5% carboxymethylcellulose (CMC). CP-154,526 displays high
affinity for the CRF-1 receptor (Ki < 10 nM) and blocks CRF-stimulated adenylate cyclase
activity in rodent pituitary and cortical membranes (Lundkvist et al. 1996; Schulz et al.
1996). Importantly, systemic injection of CP-154,526 blocks anxiety-like behavior stemming
from ethanol withdrawal in rats (Breese et al. 2005).
The Effect of CP-154,526 on the Acquisition of Ethanol-Induced Locomotor Sensitization
Mice were randomly assigned (n = 10 per group) to one of the 5 treatment conditions
in which two intraperitoneal (i.p.) injections were administered with 30-minutes between
each injection (CMC + Saline; CMC + EtOH; 5 mg/kg CP-154,526 + EtOH; 10 mg/kg CP-
154,526 + CP-154,526 + EtOH; 10 mg/kg CP-154,526 + Saline). Groups that received i.p.
injections of ethanol were compared to determine if pre-treatment with the CRF1R antagonist
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would block acquisition of ethanol-induced locomotor sensitization while groups that
received i.p. injection of saline rather than ethanol were compared to assess possible non-
specific effects of CP-154,526 on locomotor activity. The general procedure is as follows:
On days 1-10, mice were individually removed from their cage and pre-treated with an i.p.
injection of CMC or CP-154,526 (5 or 10 mg/kg). Thirty minutes later, mice received an i.p.
injection of either a 2.5 g/kg dose of ethanol (20% w/v solution, mixed in 0.9% NaCl saline)
or an equivolume injection of isotonic saline (0.9% NaCl). Mice were then returned to their
homecages and left undisturbed aside from routine animal husbandry. On day 11, all animals
were transported to the testing room in their home cages and allowed to habituate for at least
35-minutes prior to testing. A small fan provided masking noise in the testing room. Mice
were then given an i.p. injected of a 1.5 g/kg dose of ethanol prior to being placed into the
center of an open-field arena that automatically recorded activity via photo beam breaks
(Harvard Apparatus, Inc., Holliston, MA) for the 20 minute locomotor activity sessions. The
open field arena measured 40.64 cm by 40.64 cm by 30.48 cm and was made of clear
Plexiglas. Several cm of corncob bedding were placed into the open field chamber to aid in
cleaning and to prevent the buildup of odor. Soiled bedding was removed after each
locomotor activity session. Following the completion of locomotor activity testing, mice
immediately received a tail nick for the collection of 6 µl of blood in Fisher Scientific
heparinized micro-hematocrit capillary tubes (Pittsburgh, PA).
The Effect of CP-154,526 on the Expression of Ethanol-Induced Locomotor Sensitization
This paradigm used in this study has been described previously (Fee et al. 2006) and
was adapted from a design commonly used to study ethanol-induced behavioral sensitization
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(Lessov et al. 2001). All animals were transported to the testing room in their home cages
and allowed to habituate for at least 35-minutes prior to testing. A small fan provided
masking noise in the testing room. On test day 1-3, all mice received i.p. injection of isotonic
saline, based on the equivalent volume for a 1.5 g/kg dose of ethanol, prior to being placed
into the center of the open-field arena. On day 4, all mice received an i.p. injection of 1.5
g/kg dose of ethanol prior to placement in the locomotor chamber to establish a baseline of
ethanol-induced locomotor activity. Mice were then assigned to 1 of 4 treatment groups (n =
10 per group) equated for locomotor activity following the initial ethanol injection (Day 4).
All mice then underwent 10 consecutive days in which a 2.5 g/kg dose of ethanol (i.p.) was
administered in the home cage (one injection per day). The site of i.p. injection (left or right)
was alternated daily to minimize discomfort. On day 15, mice were transported to the testing
room in their home cages 35-minutes prior to testing. Thirty-minutes before i.p. injection of a
1.5 g/kg dose of ethanol, mice were pretreated with CMC or a 5, 10, or 20 mg/kg dose of CP-
154,526. The second (ethanol) injection was given contralateral to the pre-treatment injection
to minimize discomfort. Following completion of the locomotor session, mice immediately
received a tail nick for the collection of 6 µl of blood in Fisher Scientific heparinized micro-
hematocrit capillary tubes (Pittsburgh, PA).
The Effect of CP-154,526 on Basal Ethanol-induced Locomotor Activity
All animals were transported to the testing room in their home cages and allowed to
habituate for at least 35-minutes. A small fan provided masking noise in the testing room.
On test day 1-3, all mice received i.p. injection of isotonic saline, based on the equivalent
volume for a 1.5 g/kg dose of ethanol, prior to being placed into the center of the open-field
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arena. Mice were then assigned to 1 of 4 treatment groups (n = 10/group) based on average
locomotor activity over the 3 days with saline injections. On day 4, the mice were then pre-
treated with an i.p. injection of CMC or CP-154,526 (5, 10, or 20 mg/kg). Thirty minutes
later, all mice received i.p. injection of a 1.5 g/kg dose of ethanol (contralateral to the side of
pre-treatment injection) immediately before locomotor activity testing. This study allowed
for a determination of the effect of CP-154,526 on baseline ethanol-induced locomotor
activity before the development of behavioral sensitization (i.e., after the first injection).
Assessment of Blood Ethanol Concentrations
Six µl of whole blood collected from tail nicks into capillary tubes and dispensed into
12x75 mm borosilicate glass tubes containing 375 µl of water and 0.5 g of NaCl. These
liquid samples were capped and refrigerated until processing by gas chromatography. Liquid
ethanol standards (also 6 µl, 0-400 mg%) and samples were similarly prepared and heated in
a water bath at 55 °C for 10 min. Subsequently, a 1.5 ml sample of headspace gas was
removed from the glass tubes with a plastic 3.0 ml syringe and injected directly into a SRI
8610C gas chromatograph (Torrance, CA) equipped with an external syringe adapter and 1.0
ml external loading loop. Samples were run at 140°C through a Hayesep D column and
detected with FID at approximately 2 min post-inject. Hydrogen gas, carrier gas (also
hydrogen), and internal air generator flow rates were 13.3, 25, and 250 ml/min, respectively.
Areas under the curve for blood samples were analyzed with SRI PeakSimple software for
Windows running on a Dell Inspiron 3500 ® laptop computer and converted to mg% in
blood based on the curve generated for the standards.
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Data Analyses
For all experiments presented in this study, locomotor data was collect and analyzed
for all 20 minute sessions in 5 minute bins. Further analysis reveled that the effect of CP-
154,526 on ethanol-induced locomotor sensitization, when present, occurred in the first 5
minute bin of locomotor activity. For this reason, only the data from this first bin will be
presented. As a measure of sensitization to the effects of ethanol on locomotor activity,
locomotor activity on the first ethanol test day was subtracted from each of the subsequent
ethanol test day data points (activity following the second and subsequent ethanol injection –
activity following the first ethanol injection). Locomotor activity data (raw and converted)
were analyzed using analyses of variance (ANOVA). All data are presented as mean +
S.E.M. and LSD post-hot tests and t-tests (Winer et al. 1991) were used for planned
comparisons. Significance was accepted at P < 0.05 (two-tailed).
Results
CP-154,526 and Acquisition of Ethanol-Induced Locomotor Sensitization
Daily treatment with CP-154,526 prior to a sensitizing dose of ethanol (2.5 g/kg)
failed to block the development of locomotor sensitization in DBA/2J mice. A two-way
(treatment (ethanol or saline) X dose (vehicle 5 or 10mg/kg)) ANOVA revealed a significant
main effect of treatment [F(1, 45) = 14.370, p < .001] but not dose or their interaction (Figure
4.1A). This main effect of treatment suggests that repeated 2.5 g/kg ethanol injection, but
not equivolume saline, successfully induced a sensitized response to ethanol. A post-hoc t-
test comparing vehicle treated saline and ethanol treated groups confirms the existence of a
sensitized response to ethanol [t = -2.857: p < .05]. These differences in locomotor activity
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are not attributable to changes in ethanol metabolism as Figure 4.1B displays no significant
differences in blood ethanol concentrations. Additionally, these data suggest that chronic
treatment with CP-154,526 does not alter ethanol metabolism as no differences existed
between any groups.
CP-154,526 and Expression of Ethanol-Induced Locomotor Sensitization
Figure 4.2A depicts locomotor response to a 1.5 g/kg ethanol injection following
pretreatment with their respective dose of CP-154,526 in mice with a history of chronic
ethanol injection (10 days of 2.5g/kg (i.p.)). Initial ethanol responses are provided as a frame
of reference to visually demonstrate the presence of a sensitized response to ethanol.
Pretreatment of 10 and 20mg/kg CP-154,526 prior to ethanol injection effectively reduces the
ethanol-induced locomotor sensitized response observed in mice pretreated with vehicle or 5
mg/kg CP-154,526. A one-way ANOVA performed on test day data revealed a main effect of
dose [F(3, 36) = 4.502, p < .01]. LSD post hoc test revealed significant differences in both 10
and 20 mg/kg responses compared to vehicle. There were no significant differences between
vehicle and 5 mg/kg responses. To further confirm the ability of CP-154,526 to block the
expression of ethanol-induced locomotor sensitization, pair samples t tests were performed
comparing initial ethanol responses (1st Ethanol) with test day responses (12th Ethanol + CP-
154,526) at the various doses. Vehicle and 5 mg/kg CP-154,526 treated-mice show a
significantly enhanced response to ethanol, [t = -6.319: p < .001 and t = -4.404: p < .005]
respectively. Mice treated with 10 and 20mg/kg CP-154,526 exhibited no such sensitized
locomotor response to ethanol. Sensitized locomotor responses corrected for basal locomotor
activity (locomotor activity on test day - basal ethanol locomotor responses) are presented in
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Figure 4.2B. A one-way ANOVA revealed a main effect of dose [F(3, 36) = 7.212, p = .001].
LSD post hoc test revealed significant differences in both 10 and 20 mg/kg responses
compared to vehicle. Figure 4.2C represents blood ethanol concentrations collected from
ethanol-treated mice following locomotor activity. No significant differences in blood
ethanol concentrations existed suggesting that reductions in locomotor activation following
administration of CP 154,525 are not due to alterations in ethanol metabolism.
CP-154,526 and Basal Ethanol-induced Locomotor Activity
Pretreatment with CP-154,526 prior to exposure to an initial 1.5 g/kg ethanol
injection failed to alter ethanol-induced locomotor activity (Figure 4.3). A one-way (dose)
ANOVA revealed no significant main effect of dose and post-hoc LSD analysis similarly
failed to find an effect of any of the doses tested (5, 10 and 20 mg/kg) in comparison to the
0.5% CMC vehicle.
Discussion
Here, we see an interesting pattern of results emerge with the use of a CRF Receptor
1 antagonist, CP-154,526, to block the acquisition and expression of ethanol-induced
locomotor sensitization in male DBA/2J mice. Pretreatment with CP-154,526 was
ineffective in blocking the acquisition of a sensitized response to ethanol. In contrast,
pretreatment with CP-154,526 effectively blocked expression of a sensitized response in
DBA/2J mice that had been previously sensitized to the locomotor stimulating effects of
ethanol. These effects, or lack of effect as was the case with the acquisition study, were not
attributable to alterations in blood ethanol levels. Additionally, ethanol naïve DBA/2J mice
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when pretreated with CP-154,526 show no such reductions in locomotor activity in response
to ethanol. These data guard against the possibility that CP-154,526 and ethanol in
combination simply created a sedative effect and inhibited general locomotor activity. It is
also important to note that the doses utilized in this study are in the range of published doses
in rodents that have been demonstrated to produce an anxiolytic effect (Arborelius et al.
2000b; Griebel et al. 1998).
These data join a small but growing literature demonstrating the ability of
pharmacological manipulations of neurochemicals associated with the HPA axis to block
ethanol-induced locomotor sensitization. While the present results are the first direct
demonstration that CP-154,526, a CRF Receptor 1 antagonist, can be used to block the
expression of ethanol-induced locomotor sensitization, previous pharmacological studies
have established a role for CRF receptor signaling in amphetamine- (Cole et al. 1990a) and
cocaine- (Erb and Brown 2006; Przegalinski et al. 2005) induced locomotor sensitization. As
it is often hypothesized that the various drugs of abuse share at least some common
mechanisms in behavioral sensitization, CRF receptor 1 activity and/or activation of the HPA
axis may represent a point of commonality. Direct examination of HPA axis function in
future sensitization studies will help to determine if the observed results are attributable to
CRF manipulations involved in HPA axis signaling, CRF receptor function located outside of
the HPA axis, or both.
Although the current findings are promising, there are potential concerns that should
be considered. When selecting doses to block the acquisition of ethanol-induced locomotor
sensitization, a very modest range was selected. The possibility remains that a higher dose of
CP-154,526 could effectively block the acquisition of a sensitized response to ethanol.
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However, higher doses were avoided based on the long half-life of CP-154,526, t1/2 = 51h,
which has been previously published (Keller et al. 2002). Additionally, osmotic mini-pump
treatment with a 32mg/kg/day dose led to visible malaise in rats and led to uninterpretable
data in a previous study (Arborelius et al. 2000b). Doses were chosen that had been shown to
produce anxiolytic effects but minimized the possibility that daily treatment would lead to
drug accumulation and a similar malaise. The question also remains if the observed effects of
CP-154,526 are due to the drug’s peripheral or central actions. CP-154,526 is known to
easily cross the blood brain barrier and achieve peak concentrations 20 minutes after
intravenous (i.v.) administration (Keller et al. 2002) as well as produce anxiolytic effects 30
minutes following intraperitoneal administration (Griebel et al. 1998), but this fact does not
eliminate the possibility that the observed effects of the compound are attributable to its
actions in the periphery. However, CRF1R expression is more prominent in the CNS and it is
the CRF type 2 Receptor (CFR2R) that is more widely distributed in the periphery (Chatzaki
et al. 2006). Although this investigation cannot definitively address this concern, the existing
literature on behavioral sensitization would suggest that this is not the case. Central
administration of CRF via intracerebroventricular (i.c.v.) canulla promotes the development
of locomotor sensitization to d-amphetamine (Cador et al. 1993) while i.c.v. administration
of a CRF antagonist blocked the expression of stereotypy in response to amphetamine (Cole
et al. 1990a). These studies suggest that CRF activity in the CNS is critical to the
development and/or attenuation of a sensitized response to drug. For this reason, we conclude
that the observed ability of CP-154,526 to block the expression of ethanol-induced locomotor
sensitization is most likely due to its activity within the central nervous system.
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Increased sensitivity to behavioral sensitization may be an underlying mechanism that
increases the risk for developing drug dependence. According to one view, repeated exposure
to a drug promotes neuronal reorganization leading to a hypersensitive state in brain reward
circuitry, presumably increasing sensitivity to the positive reinforcing value of a drug
(Robinson and Berridge 1993; 2000; 2001). Viewed this way, increased drug-seeking
behavior is driven by the heightened reinforcement resulting from chronic drug intake. An
alternative view of drug-induced neuronal reorganization is the allostasis model of drug
dependence. The allostasis model suggests that neuroplastic changes following repeated,
intermittent drug exposure increases negative emotional reactions in addicted individuals
(Koob 2003; Koob and Le Moal 2001). Chronic exposure to stressors, including drugs,
promote changes to the processes that maintain the system’s emotional “set point”, such that
a “normal” emotional state can only be achieved in the presence of the drug. Thus, in
addicted individuals, the negative emotional reaction resulting from the absence of drug
drives drug-seeking behavior via negative reinforcement (i.e., drug alleviates the negative
affective state) (Koob 2003).
Procedures that support behavioral sensitization involve repeated and intermittent
exposure to ethanol, which may be considered analogous to the repeated cycles of excessive
consumption and abstinence characteristic of alcohol dependent individuals. Viewed this
way, behavioral sensitization may be a useful model for assessing neurochemical changes
proposed by the allostasis model. While a CRF receptor antagonist has been shown to block
the expression of cocaine-induced locomotor sensitization (Erb and Brown 2006), a role for
CRF signaling in modulating ethanol-induced behavioral sensitization has yet to be
examined. However, there are data in the literature suggesting a possible role for CRF. In
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addition to increasing CRF activity (Koob et al. 1993; Rasmussen et al. 2000; Rivier et al.
1984), ethanol exposure has been shown to increase ACTH (Rivier et al. 1984; Rivier and
Lee 1996) and corticosterone levels (Rivier et al. 1984), hormones, which together with CRF,
constitute the stress-activated hypothalamic-pituitary-adrenal axis. Interestingly, restraint-
induced stress can substitute for ethanol injections in the acquisition of behavioral
sensitization in mice. Furthermore, administration of a glucocorticoid receptor antagonist,
RU38486, blocks sensitized responses to ethanol (Roberts et al. 1995). In the present report,
we determined if another component of the HPA axis, namely CRF, modulates ethanol-
induced behavioral sensitization.
Given the ubiquitous expression of CRF throughout the rodent brain (Cummings et
al. 1983), the current findings beg the question of the anatomical location for CP-154,526’s
effects. It stands to reason that an examination of the ethanol sensitization literature in
combination with the CRF literature may provide some insight. Several candidate brain
regions emerge when looking to the ethanol locomotor sensitization literature. A 1997 study
by Nestby and colleagues found that repeated treatment with ethanol lead to increased
reactivity of dopaminergic and cholinergic neurons of the nucleus accumbens and the
striatum (Nestby et al. 1997b). Additional evidence for the involvement of the striatum in
ethanol induced-locomotor sensitization is found in the dopamine literature. Mice expressing
ethanol-induced locomotor sensitization show significant increases in dopamine D2 binding
sites in the striatum compared to controls (Souza-Formigoni et al. 1999). The striatum and
the nucleus accumbens both represent possible points of overlap between regions of known
CRF expression and CRF neuronal innervation (Cummings et al. 1983) and brain regions
previously implicated in ethanol-induced locomotor sensitization. However, the alternate
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hypothesis still remains that CP-154,526 is modulating CRF Receptor 1 signaling in alternate
region or regions that ultimately influences an ethanol sensitized response in the striatum or
accumbens. The central nucleus of the amygdala (CeA) is one such brain region that has been
demonstrated to play a critical role in CRF signaling (Cummings et al. 1983) but has also
been implicated in a variety of behaviors associated with addiction. Increased cocaine-
induced release of CRF occurs in the CeA of rats repeatedly treated with cocaine (Richter et
al. 1995). It was also shown that corticosterone implantation in newborn rats (postnatal day
0-12) leads to higher locomotor activity in adulthood as assessed by plus maze activity
(Roskoden et al. 2005). The aforementioned result was found to be accompanied by a
decreased number of CRF containing neurons in the CeA of corticosterone treated rats
(Roskoden et al. 2005). The ethanol literature also provides some interesting evidence for the
involvement of the CeA in ethanol-dependant animals. Administration of the CRF
antagonist, D-Phe-CRF(12-41), directly into the CeA blocked the increased ethanol self-
administration of ethanol-dependant rats during acute withdrawal (Funk et al. 2006).
Additionally, acute withdrawal is characterized by a reduced CRF immunoreactivity in the
CeA suggesting a potentiated release of CRF in this region (Funk et al. 2006). Third party
modulation of ethanol-induced locomotor sensitization by CRF in the CeA certainly
represents a promising avenue for future investigations. Alternately, CRF’s role in the
paraventricular nucleus of the hypothalamus (HPA axis activation) could also serve as a
fertile target when investigating if CRF Receptor 1 activity in the expression of ethanol-
induced locomotor sensitization is site-specific.
These findings suggest that CRF Receptor 1 signaling may represent an interesting
avenue in the treatment of alcoholism. CP-154,526 was effective in blocking a sensitized
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locomotor response to ethanol; a behavior thought to be reflective of reward associated with
drug administration. Unfortunately, pretreatment with CP-154,526 was unable to block the
acquisition of a sensitized response in mice and therefore might not be the best target for a
prophylactic treatment in high risk populations. However, a pharmacological intervention
that is capable of blocking the expression of a sensitized response in drug dependant
individuals might be more clinically useful than one aimed at blocking the acquisition of a
sensitized drug response as the former population would be far easier to identify than the
latter. More testing with CP-154,526 is necessary before theses aims can be realized but these
data represent a promising step in this direction.
Taken together these data provide the first direct evidence a CRF Receptor 1
antagonist’s, CP-154,526, ability to block the expression of ethanol-induced locomotor
sensitization in DBA/2J mice. This was an effect that was not attributable to alterations in
ethanol metabolism or a basic pharmacological interaction producing sedation. Future studies
are required to determine the exact mechanisms by which this modulation of CRF signaling
is capable of blocking the expression of a sensitized behavior. Additionally, these data
evaluated in light of the finding by Roberts and colleagues (1995) which demonstrate a
glucocorticoid receptor antagonist’s ability to block the acquisition of ethanol-induced
locomotor sensitization suggests that antagonism of receptors associated with HPA axis
signaling is not one size fits all. Further investigation is necessary to determine why a
blockade of corticosterone signaling and CRF1R signaling are not functionally equivalent
with respect to their ability to block the acquisition of ethanol-induced locomotor
sensitization.
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Figure 4.1 Effects of CP-154,526 on the acquisition of ethanol-induced locomotor
sensitization in male DBA/2J mice. (A) Mice received either pretreatment with CP-154,525
(Vehicle, 5, or 10mg/kg) prior to 2.5 g/kg ethanol or pretreatment with CP-154,525 (Vehicle
or 10mg/kg) prior to equivolume saline for ten consecutive days. One Test Day, mice
received a 1.5 g/kg ethanol injection prior to placement in the locomotor chamber. Mice
receiving chronic 2.5 g/kg ethanol injections were significantly more active than mice
receiving saline injection. Pretreatment with CP-154,526 had no effect on the acquisition of
cross-sensitization in animals receiving stress and 10mg/kg CP-154,526 pretreatment had no
effect on the general locomotor activity of saline-treated mice. (B) Blood ethanol
concentrations (mg%) in DBA/2J mice. Immediately following locomotor activity
assessment after final ethanol injection (acquisition test day), mice had tail blood collected
for analysis using gas chromatography to assess the possibility of alterations in ethanol
pharmacokinetics. There were no differences in any of the groups tested. All values reported
are mean + SEM.
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Figure 4.2 Effect of CP-154,526 on the expression of ethanol-induced locomotor
sensitization in male DBA/2J mice. (A) represents locomotor responses were recorded
following a 1.5 g/kg ethanol injection following pretreatment with their respective dose of
CP-154,526 in mice with a history of chronic ethanol injection (10 days of 2.5g/kg (i.p.)).
Initial ethanol responses are provided as a frame of reference to visually demonstrate the
presence of a sensitized response to ethanol. Pretreatment of 10 and 20mg/kg CP-154,526
prior to ethanol injection effectively reduces the ethanol-induced locomotor sensitized
response observed in mice pretreated with vehicle or 5 mg/kg CP-154,526. (B) represents the
expression of locomotor sensitization by presenting test day ethanol exposure corrected for
baseline ethanol activity (12th ethanol activity minus 1st ethanol activity). (C) Blood ethanol
concentrations (mg%) in DBA/2J mice. Immediately following locomotor activity
assessment of 12th ethanol injection, mice had tail blood collected for analysis using gas
chromatography to assess the possibility of alterations in ethanol pharmacokinetics. There
were no differences in any of the groups tested. All values reported are mean + SEM.
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Figure 4.3 Acute effects of CP-154,526 on ethanol-induced locomotor activity in male
DBA/2J mice. Pretreatment with CP-154,526 30 min prior to exposure to an initial 1.5 g/kg
ethanol injection failed to alter ethanol-induced locomotor activity. All values reported are
mean + SEM.
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CHAPTER 5 
GENERAL DISCUSSION 
 
Summary of Experimental Findings 
 
In the present report, RII-/- mice consistently showed significantly greater ethanol-
induced locomotor activity relative to RII+/+ mice. RII-/- mice also showed increased 
sensitivity to ethanol-induced locomotor sensitization, an effect that may be dependent on 
genetic background and/or testing paradigm. Importantly, increased locomotor activity by 
RII-/- mice was specific to ethanol injections (and not seen following saline injections), and 
was not associated with altered blood ethanol levels. Normal blood ethanol levels and ethanol 
metabolism by RII-/- mice have previously been documented (Fee et al. 2004; Thiele et al. 
2000b)Since RII-/- mice show blunted PKA activity in critical brain regions, such as the 
striatum and nucleus accumbens (Brandon et al. 1998; Thiele et al. 2000b), the present 
results suggest that normal PKA signaling is part of a mechanism that protects against 
ethanol-induced locomotor activity and behavioral sensitization. 
 To extend these findings, the RII knockout mouse model was utilized to determine if 
enhanced sensitivity to stress was a factor contributing to the expression of heightened 
sensitivity to ethanol-induced locomotor activation in these mice. A commonly employed 
restraint stress cross-sensitization paradigm was employed which has been previously 
demonstrated to produce a cross-sensitized locomotor response to ethanol in our hands and in 
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other laboratories. RII-/- mice failed to show a heightened sensitivity to the effects of 
restraint stress on ethanol-induced locomotor activation when compared to RII+/+ mice. 
Chronic restraint stress induced a hypersensitive response to ethanol compared to non-
stressed controls in both RII-/- and RII+/+ mice with no genotype differences in the 
magnitude of this response. Additional studies were performed demonstrating the ability of 
chronic exposure to restraint stress to induce a cross-sensitized response to ethanol in two 
commercially available inbred strains of mice, C57BL/6J and DBA/2J. In an attempt to 
discern a mechanism for the contribution of stress exposure to a cross-sensitized response to 
ethanol, pretreatment with CRF Receptor 1 antagonist, CP-154,526, prior to restraint stress 
sessions in male DBA/2J mice was employed in an attempt to block the acquisition of cross-
sensitization. Ultimately this approach was ineffective in blocking the acquisition of restraint 
stress-induced cross-sensitization; an effect that was rather unexpected given the 
demonstrated efficacy of the glucocorticoid receptor antagonist, RU38486 (Roberts et al. 
1995). 
Despite the lack of effect observed when testing CP-154,526’s ability to block the 
acquisition of a cross-sensitized response to ethanol, its ability to block both the acquisition 
and expression of ethanol-induced locomotor was investigated. This was a logical next step 
given the fact that RU38486 has also been shown to block the acquisition of ethanol-induced 
locomotor sensitization (Roberts et al. 1995). An interesting pattern of results emerges with 
the use of a CRF Receptor 1 antagonist, CP-154,526, to block the acquisition and expression 
of ethanol-induced locomotor sensitization in male DBA/2J mice.  Pretreatment with CP-
154,526 was ineffective in blocking the acquisition of a sensitized response to ethanol. In 
contrast, pretreatment with CP-154,526 effectively blocked a sensitized response in DBA/2J 
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mice that had been previously sensitized to the locomotor stimulating effects of ethanol. 
These effects, or lack of effect as was the case with the acquisition study, were not 
attributable to alterations in blood ethanol levels. Additionally, ethanol naïve DBA/2J mice 
when pretreated with CP-154,526 show no such reductions in locomotor activity in response 
to ethanol. These data guard against the possibility that CP-154,526 and ethanol in 
combination simply created a sedative effect and inhibited general locomotor activity. It is 
also important to note that the doses utilized in this study are in the range of published doses 
demonstrated to produce an anxiolytic effect in mice (Arborelius et al. 2000b; Griebel et al. 
1998). 
 
Proximate Mechanisms Investigated in Locomotor Sensitization 
 While the present results serve as the first direct demonstration that PKA signaling 
modulates the stimulant effects of ethanol and ethanol-induced behavioral sensitization, 
previous pharmacological and genetic studies have established that PKA signaling is 
involved with amphetamine- (Crawford et al. 2004; Crawford et al. 2000; Tolliver et al. 
1999) and cocaine- (Miserendino and Nestler 1995; Park et al. 2000; Schroeder et al. 2004) 
induced locomotor sensitization. Of direct relevance to the present report is the observation 
that RII-/- mice are more susceptible to the acquisition of locomotor sensitization following 
repeated amphetamine exposure (Brandon et al. 1998). Interestingly, repeated amphetamine 
exposure reduces PKA activity in the nucleus accumbens and striatum (Crawford et al. 2004; 
Crawford et al. 2000). Thus, we speculate that reduced PKA signaling in these regions causes 
RII-/- mice to be more sensitive to the stimulant effects of ethanol as well as ethanol- and 
amphetamine-induced behavioral sensitization. Because dynorphin, a neuropeptide that is 
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reduced in the dorsal medial striatum of RII-/- mice (Brandon et al. 1998), plays an 
inhibitory role in sensitization (Heidbreder et al. 1995), it can be speculated that increased 
ethanol- and amphetamine-induced behavioral sensitization in  RII-/- mice may be the result 
of low striatal dynorphin activity. However, we suggest that a degree of caution is necessary 
in that it is still unclear to what extent, if any, the neuronal mechanisms involved in ethanol- 
and amphetamine-induced locomotor sensitization overlap. 
 The RII-/- model represents a unique opportunity to determine if alterations in PKA 
signaling will affect the expression of stress-induced cross-sensitization to ethanol in mice. 
There is considerable evidence in the literature suggesting a role for PKA activity in the 
regulation of HPA axis activity. The effects of diazepam on HPA axis activity are mediated 
via cAMP-dependant PKA activity in the hypothalamus (Vargas et al. 2001). PKA activity 
has also been posited as a mechanism underlying the diminished hippocampal activity 
believed to be associated with the HPA axis hyperactivity in depression (Perera et al. 2001). 
Specifically, ethanol has been shown to increase PKA and cAMP activity and, in turn, 
increase CRF peptide secretion (Li et al. 2005). Additionally, PKA activity has been shown 
to play an essential role in CRF mediated decreased expression of CRF receptor 1 mRNA in 
part via the phosphorylation of cAMP response element binding (CREB) (Kasagi et al. 
2002). Ultimately, it appears the alterations in PKA signaling observed in the RII knockout 
model which contribute to differences in ethanol-induced locomotor sensitization are not 
responsible for the alterations in ethanol responsivity that accompany chronic exposure to 
stress. However, it is possible the employed stress paradigm failed to reveal genotype 
differences because it effectively created a hypersensitive response in both knockout and 
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wildtype mice; a less intense stress paradigm could have allowed for genotype 
discrimination.  
Although the RII model failed to provide a specific mechanism for the contribution 
of stress to a cross-sensitized locomotor response to ethanol, further focus was given to a 
neuropeptide associated with the HPA axis, CRF, due to the demonstrated ability of 
pharmacological interventions in HPA axis signaling to alter the acquisition and expression 
of sensitized responses.  In examining a role for stress signaling in sensitization, the 
physiological endpoint, cortisol in humans and corticosterone in rodents, is often targeted. 
Adrenalectomy eliminates the synthesis and release of corticosterone, and has been shown to 
block the acquisition of cocaine sensitization if performed prior to the sensitization regime. 
However, if the sensitization paradigm is initiated prior to adrenalectomy, the expression of 
cocaine sensitization remains intact (Przegalinski et al. 2000).  Prasad and colleagues also 
find a similar inability of adrenalectomy to alter the expression of cocaine-induced locomotor 
sensitization, but it was also reported that adrenalectomy blocks the acquisition of 
sensitization when tested in acute withdrawal (24 hrs) but not in late withdrawal at 1 week 
(Prasad et al. 1996). Taken together these studies suggest the importance of glucocorticoid 
signaling in the acquisition of sensitized behaviors. Additionally, pretreatment with the 
glucocorticoid receptor antagonist, mifepristone, blocks the expression of a sensitized 
locomotor response to amphetamine, while the drug had no effect on amphetamine responses 
in drug naïve rats (De Vries et al. 1996). Roberts et al. (1995) also found that RU38486 could 
block the acquisition of ethanol-induced locomotor sensitization and restraint stress-induced 
cross-sensitization to ethanol in mice. These findings point to the level of glucocorticoid 
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signaling and subsequent receptor binding and activation as being critical to the development 
of behavioral sensitization. 
Alterations in HPA axis signaling upstream of glucocorticoid release have also been 
implicated in behavioral sensitization. Intracerebroventricular (i.c.v.) administration of the 
CRF antagonist, G-helical CRF, reduced stereotypic response to amphetamine following 
repeated restraint stress in rats (Cole et al. 1990a). In contrast, an augmentation of HPA axis 
signaling via pharmacological manipulation can result in the expression of sensitized 
behaviors. I.c.v. administration of CRF rather than subcutaneous administration of CRF leads 
to long-term locomotor sensitization to D-amphetamine (Cador et al. 1993). Similarly, 
microinfusion of CRF into the shell of the nucleus accumbens of rats led to a prolonged 
increase in general locomotor activity (Holahan et al. 1997). Previous pharmacological 
studies with CP-154,526 have established a role for CRF receptor signaling in cocaine- (Erb 
and Brown 2006; Przegalinski et al. 2005) induced locomotor sensitization. After finding a 
prominent role for neurochemicals associated with HPA axis activity, specifically CRF 
signaling, in the sensitization literature, it was a logical step to determine if a role for CRF 
Receptor 1 signaling existed in the acquisition and expression of ethanol-induced locomotor 
sensitization.  
CP-154,526 pretreatment in mice previously exposed to the sensitization paradigm 
effectively blocked the expression of ethanol-induced locomotor sensitization. This points to 
the idea that once established, neuroplastic changes associated with the development of 
sensitization can be modulated by CRF signaling. In contrast, it was interesting to find that 
chronic pretreatment with CP-154,525 failed to protect against the acquisition of locomotor 
sensitization that accompanies repeated ethanol exposure. This finding suggests the 
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possibility that the plastic changes associated with ethanol-induced locomotor sensitization 
can be achieved despite a pharmacological blockade of CRF 1 receptors. Taken together, 
these two pieces of evidence suggest that CRF receptor 1 signaling plays a complimentary 
role in the development and expression of sensitization. It appears that blockade of CRF1Rs 
will not prevent the development or reverse the changes associated with heightened 
behavioral sensitization, but it might help to modulate mechanisms associated with the 
expression of sensitized behaviors. 
The question remains if the observed effects of CP-154,526 are due to the drug’s 
peripheral or central actions. CP-154,526 is known to easily cross the blood brain barrier and 
achieve peak central concentrations 20 minutes after intravenous (i.v.) administration (Keller 
et al. 2002) as well as produce anxiolytic effects 30 minutes following intraperitoneal 
administration (Griebel et al. 1998), but this fact does not eliminate the possibility that the 
observed effects of the compound are attributable to its actions in the periphery. However, 
CRF receptor 1 expression is more prominent in the CNS and it is the CRF 2 Receptor 
(CFR2R) that is more widely distributed in the periphery (Chatzaki et al. 2006). Future 
studies examining the effects of peripheral verses central administration of CP-154,526 on 
ethanol-induced locomotor sensitization and the corresponding levels of ACTH and 
corticosterone may provide insight into the anatomical location of action.  
It is curious that the more or less constant presence of CRF receptor 1 antagonism in 
the acquisition studies failed to block both ethanol-induced locomotor sensitization and the 
restraint stress-induced cross-sensitized response to ethanol. Considering these results in light 
of the findings by Ohata et al. (2002) which demonstrated the ability of a CRF1R antagonist, 
CRA1000, to attenuate restraint stress-induced ACTH and corticosterone release 2h but not 
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26h after final CRA1000 treatment, it seems possible that the observed results might be 
explained by the ability of CP-154,526 to exert short-term rather than long-term effects on 
CRF1R signaling within the HPA axis effectively reducing the release of ACTH and 
corticosterone. However, the paraventricular nucleus of the hypothalamus is just one site of 
CRF1R expression and the possibility remains that CRF receptor 1 signaling in any number 
of alternate brain regions could have mediated the observed reductions in the expression of 
ethanol-induced locomotor sensitization. Some of these regions will be discussed in the 
following section as they relate to proposed models of drug abuse and addiction.  
 
Ultimate Mechanisms Related to Sensitization 
 In order for the aforementioned studies to be relevant in the broader sense of drug use 
and addiction, it is important to view sensitization in the context of the current theories of 
drug addiction. The incentive sensitization model put forth by Robinson and Berridge 
provides an explanation for the initiation of drug use, the continuation of this behavior, and 
the escalation of use that accompanies addiction (Robinson and Berridge 1993; 2000; 2001). 
On the other hand, the allostasis model offered by George Koob suggests that neuroplastic 
changes involved in our emotional regulation become dysregulated with chronic exposure 
and in turn, increase the likelihood of future use (Koob 2003; Koob and Le Moal 2001). A 
role for locomotor sensitization exists in both theories of drug use and abuse. However, the 
most important question still remains. Is the locomotor activation observed in locomotor 
sensitization purely a motor output free of psychological control or is it reflective of a 
psychological state (e.g. drug seeking/reinforcement)? The answer to this question will 
ultimately determine the relative importance of locomotor sensitization in the two models of 
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drug addiction and will help to predict which pharmacological interventions will be most 
affective in preventing the development and expression of these behaviors. 
 On the most basic level, the idea of drug-induced locomotor sensitization fits well 
with the incentive sensitization model of drug addiction. The locomotor activation in 
response to drug is believed to be predictive of its rewarding properties and repeated 
administration of drug, a schedule utilized in sensitization paradigms, leads to significantly 
enhanced locomotor activation. The sensitized locomotor response is therefore reflective of a 
sensitized reward system and individuals receiving a hypersensitized response to reward 
should be more vulnerable to future abuse and addiction. Physiological assessments of 
neurotransmitter release in brain regions associated with reward confirm this idea of a 
sensitized reward system. Amphetamine-locomotor sensitization is associated with enhanced 
stimulated dopamine release in the dorsal and ventral striatum (Paulson and Robinson 1995). 
Nicotine-induced behavioral sensitization is also associated with heightened extracellular 
dopamine release in the striatum and nucleus accumbens (Shim et al. 2001). Enhanced 
responsiveness of accumbal dopaminergic and cholinergic neurons has been observed 
following repeated administration of ethanol, morphine, cocaine and amphetamine (Nestby et 
al. 1997b). Chronic cocaine treatment has also been shown to produce a sensitized release of 
glutamate in the accumbens (Reid and Berger 1996). The functionality of striatal dopamine 
transporters has also been implicated in locomotor sensitization (Claye et al. 1995) 
suggesting that changes in extracellular neurotransmitter release may only be part of the 
emerging picture. 
Although a significant subset of the behavioral sensitization literature points to 
sensitization of signaling mechanisms found within the prominent reward pathways; this is a 
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nuanced literature. Recent studies suggest that a basic locomotor response to drug is not 
always sufficient to establish this connection with reward. A study by Allen and colleagues 
demonstrates that rats selected for their low locomotor response to cocaine, but not rats 
exhibiting high locomotor responses, will later exhibit cocaine-induced locomotor 
sensitization and conditioned-place preference (Allen et al. 2007). It seems possible that 
mechanisms associated with reward are not of primary importance when sensitization is only 
possible in a population of rats selected for their initially low responding. Additionally, a 
mechanistic sensitization is not always a hallmark of locomotor sensitization. Behavioral 
sensitization following repeated ethanol has been observed in C57BL/6J and DBA/2J mice in 
the absence of an enhanced dopaminergic response in the nucleus accumbens of these mice 
(Zapata et al. 2006).This dissociation between reward and sensitization is also present in a 
study by Hodge and colleagues which found that mice exhibiting low levels of ethanol self-
administration were most sensitive to ethanol-induced locomotor sensitization (Camarini and 
Hodge 2004). These studies, particularly those by Allen (2007) and Camarini (2004), suggest 
the possibility that enhanced initial sensitivity to the rewarding aspects of drug might not be 
the best predictor of a future sensitized response. 
 The incentive sensitization model places great focus on the rewarding aspects of drug 
use and abuse but the negative affect and emotional dysregulations that accompanies drug 
addiction is difficult to explain when focused purely on reward circuits. However, it is 
possible that negative affect and the resultant drive to eliminate said affect enhances the 
incentive salience of drug and encourages future drug use. Alternatively, the allostasis model 
put forth by Koob might provide more emphasis on the emotional component of drug use and 
the subsequent dysregulations of neuropeptide systems that is well documented in chronic 
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drug exposure (Koob 2003; Koob and Le Moal 2001). This model provides the opportunity 
to test a variety of compounds on behaviors associated with dependence. Antagonism of 
CRF, the major neuropeptide existing in a reciprocal balance with Neuropeptide Y (NPY), is 
a prime target for alleviating the negative affect associated with drug dependence and 
withdrawal. Administration of the CRF antagonist, D-Phe-CRF(12-41), directly into the CeA 
blocked the increased ethanol self-administration of ethanol-dependant rats during acute 
withdrawal (Funk et al. 2006). The ability of CRF antagonists to block dependence and 
withdrawal driven-behaviors certainly strengthens this idea of allostatic modulation of 
behavior. Similarly, the present study uncovers a role for CRF receptor signaling in the 
expression of ethanol-induced locomotor sensitization. Given this result, it seems possible 
that in addition to representing a model of a sensitized reward system, it may also be used as 
a fairly simple model of ethanol dependence. It is of interest to determine if pharmacological 
interventions aimed at alleviating the negative emotionality associated with dependence or 
compounds aimed at preventing a heightened reward state ultimately prove more efficacious 
in blocking sensitized behaviors.   
 The model of dependence upon which one focuses will suggest various brain regions 
as being of particular interest. The nucleus accumbens quickly presents itself in the reward 
literature. CRF activity in nucleus accumbens shell but not core has been linked to increases 
in general locomotor activity (Holahan et al. 1997). More directly related to drug taking 
behavior, pharmacological blockade of CRF1R signaling in the nucleus accumbens resulted 
in significantly reduced cocaine-induced dopaminergic overflow in the accumbens (Lodge 
and Grace 2005). I.c.v. infusion of CP-154,526 also reduced extracellular concentrations of 
dopamine in the nucleus accumbens and ventral tegmental area following cocaine injection 
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(Lu et al. 2003). Exogenous administration of CRF via microinjections into the medial shell 
of the nucleus accumbens enhanced cue-induced responding for sucrose (Pecina et al. 2006). 
 The amygdala has similarly demonstrated its importance in the modulation of 
emotionality as well as the emotional dysregulations that accompanies chronic exposure to 
drug and the resulting dependence. CRF signaling has been shown to play a critical role in 
amygdaloid function. CRF activity modulated via the exogenous application of a CRF 
receptor 1 and 2 agonist, urocortin, into the basolateral amygdala resulted in anxiety-like 
behavior in rats and was suggested to underlie the plastic changes in emotional 
dysregulations (Rainnie et al. 2004). In a related experiment, exposing sheep to predator 
stress (dog) results in increased CRF and GABA release in the amygdala as well as CRF 
release in the PVN (Cook 2004). CRF1R activity in the amygdala has also been implicated in 
the defensive posturing that follows acute social defeat in mice (Robison et al. 2004) and has 
been hypothesized to modulate the development of an exaggerated fear response following 
exposure to intense stress. As previously mentioned, CRF activity in the CeA has also been 
shown to be particularly important in the ethanol self-administration of dependant rats 
following ethanol-withdrawal (Funk et al. 2006). Alternatively, CRF function in the 
amygdala has also been associated with drug-related phenotypes typically associated with 
reward. Infusion of CP-154,526 into the amygdala as well as the nucleus accumbens of rats 
attenuates morphine-induced reinstatement of morphine conditioned place preference (Wang 
et al. 2006). Taken together the studies mentioned above all point to a critical role for CRF 
signaling in the amygdala, but it is also important to consider a role for amygdaloid function 
in behavioral sensitization. It is of interest to note that low-current electrical stimulation of 
the central nucleus of the amygdala significantly increased the magnitude of concurrent d-
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amphetamine-induced locomotor sensitization (Gelowitz and Kokkinidis 1993). Related to 
stress-induced cross-sensitization, the heightened locomotor response to amphetamine in rats 
repeatedly receiving social defeat stress has been linked to enhanced Fos activity in the VTA 
and the amygdala (Nikulina et al. 2004). Given the wide-ranging role for the various sub-
regions of the amygdala, it stands to reason that CRF activity in the amygdala could 
contribute to behaviors representing any number of underlying mechanisms associated with 
drug use and abuse.  
This brief review of CRF1R’s role in behavioral sensitization focuses on just a few of 
the brain regions which are potentially importance in the expression of ethanol-induced 
locomotor sensitization. Unfortunately, the studies described above are unable to determine 
the exact mechanism of action by which CP-154,526 achieves its attenuation of ethanol-
induced locomotor sensitization. Site-specific infusion of CP-154,526 into various brain 
regions, including the paraventricular nucleus of the hypothalamus, amygdala, nucleus 
accumbens, VTA, and striatum, would assure the presence of drug at the proposed site of 
action and would also allow for a more systematic approach to the identification of brain 
regions essential to blocking ethanol-induced locomotor sensitization. The possibility 
remains that CRF1R function in any set of brain regions, alone or in concert, could be 
mediating the expression of ethanol-induced locomotor sensitization.  
Ultimately, no one model of drug abuse and dependence will provide a complete 
explanation for a specific situation. Additionally, assessments of HPA axis function as well 
as stress history are modulating variables that can interact with each of the models discussed 
above. Just as there is no one explanation for the etiology of alcoholic abuse, sensitization 
research can fit anywhere in the continuum between the reward associated with initial drug 
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responses to a representation of the dysregulated emotionality of a drug-dependant state. 
Ultimately, the locomotor activation that accompanies sensitization would take on very 
different meanings given the respective model of dependence. This does not eliminate the 
possibility that the same behavior could be exhibited for very different reasons. However, 
regardless of its origin, locomotor sensitization provides a powerful screening tool to 
determine the efficacy of compounds associated with both models of dependence and will 
continue to due so far into the future.  
 
Implications of Current Findings 
Alterations in markers upstream of PKA signaling, adenylyl cyclase activity, have 
been observed in alcoholic populations (Pauly et al. 1999; Yamamoto et al. 2001). 
Additionally, alterations in PKA activity via the deletion of the regulatory subunit II
enhance sensitivity to ethanol-induced locomotor sensitization (Fee et al. 2006). These 
finding suggests the possibility that pharmaceuticals aimed at altering PKA signaling might 
be a useful tool in the treatment of alcohol and other drugs of abuse. However, the rather 
ubiquitous expression of PKA throughout the brain, the bi-direction nature of PKA signaling 
varying from brain region to region, and its involvement in virtually every g-protein coupled 
receptor all point to the unfortunate likelihood that the unintended and unpredictable side 
effects of these treatments preclude their viability. 
Chronic exposure to stress imparts a powerful vulnerability to subsequent drug 
exposure. The ability of stress to reinstate both drug seeking (Erb et al. 2001; Wang et al. 
2005) and the resumption of drug taking (Covington et al. 2005; Kabbaj et al. 2001) has been 
well documented. For these reasons, compounds exhibiting the ability to alter the stress 
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response and/or attenuate signaling associated with HPA activation could be invaluable tools 
in the treatment of drug addiction.  Along these lines, Shaman and colleagues found that 
pretreatment with CP-154,526 attenuated footshock-induced drug-seeking in both heroin- 
and cocaine-trained rats (Shaham et al. 1998). The inability of CP-154,526 to block the 
acquisition of restraint stress-induced cross-sensitization to ethanol and ethanol locomotor 
sensitization contrasted with the efficacy of RU38486 suggest that glucocorticoid signaling 
may ultimately provide a more feasible target for the prevention of the acquisition of a 
sensitized response to drug. For this reason, in populations with a documented drug addiction 
diathesis, such as the children of alcoholics, prophylactic treatment with a glucocorticoid 
antagonist prior to drug exposure may help slow or prevent the progression from casual use 
to abuse. However, these proposed treatments may prove ineffective due to the rapid 
adaptation possible within the HPA axis, potential side effects (e.g. RU38486’s efficacy as a 
contraceptive), and interactions due to the system’s ubiquitous expression.   
The presented findings suggest that CRF Receptor 1 signaling may represent an 
attractive avenue in the treatment of alcoholism. CP-154,526 was effective in blocking a 
sensitized locomotor response to ethanol; a behavior thought to be reflective of reward 
associated with drug administration. This idea is evidenced by the fact that mice with low 
ethanol self-administration put through a sensitization paradigm will consume high amounts 
of ethanol in future self-administration sessions (Camarini and Hodge 2004). Unfortunately, 
pretreatment with CP-154,526 was unable to block the acquisition of a sensitized response in 
mice and therefore might not be the best target for a prophylactic treatment in high risk 
populations. However, a pharmacological intervention that is capable of blocking a sensitized 
response in drug dependant individuals could be more clinically useful than one aimed at 
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blocking the acquisition of a sensitized drug response as the former population would be far 
easier to identify than the latter. It seems more likely that a patient will present after ethanol 
dependence or addiction has been crystallized rather than the critical but brief initial move 
from use to abuse. More testing with CP-154,526 is necessary before theses aims can be 
realized but these data represent a promising step in this direction.  
 
Possible Future Directions 
 The RII knockout remains an interesting model for the study of drug sensitization. 
Given the enhanced sensitivity to both ethanol and amphetamine, it stands to reason that RII
knockout mice will show enhanced sensitivity to sensitization when other drugs of abuse are 
administered. Ethanol is known for its wide-ranging effects on a variety of neurotransmitter 
systems. The use of drugs of abuse with more specific mechanisms of action in the 
examination of cross-sensitized responses to ethanol might help to elucidate the role of PKA 
signaling in ethanol-induced locomotor sensitization. Alternatively, the rescue of PKA 
signaling via the expression of RII subunit via viral vector technology will provide a 
powerful tool in assessing the candidate brain regions involved in ethanol-induced locomotor 
sensitization as well as further validate the model.  
The present findings demonstrating the ability of CP-154,526 to block the expression 
of ethanol-induced locomotor sensitization suggest a role for the activation of CRF1 
receptors in sensitized locomotor behaviors. However, the neuroanatomical location of these 
rather diffusely expressed CRF1 receptors remains unclear. The hypothalamus, amygdala, 
nucleus accumbens, and striatum have all surfaced as potential candidate regions and site-
specific treatment with CP-154,526 may uncover a regional specificity in CP-154,526’s 
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effect on the expression of ethanol-induced locomotor sensitization. The difficulty of these 
experiments would be compounded by the possibility that CRF signaling in a concert of brain 
regions is critical to the expression of sensitized behaviors. Regardless, regional specificity of 
CRF1 signaling has been demonstrated in research investigating ethanol drinking in 
dependant rats and should be possible in ethanol-sensitization studies as well. 
In summary, these data suggest a novel role for the involvement of PKA activity in 
the acquisition of ethanol-induced locomotor sensitization. Additionally, a role for CRF 
receptor 1 signaling was discovered in the expression of ethanol-induced locomotor 
sensitization. Together these findings suggest new avenues of research which will lead to a 
greater understanding of the mechanisms involved in behavioral sensitization. 
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